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ABSTRACT 
 
             The present study was aimed to prepare colon targeted tablets containing Tramadol 
HCl as active pharmaceutical agent and Eudragit E100 and Eudragit S100 as pH dependent 
polymers and to study the effect of these polymers on drug release rate. Different layers of 
polymers has been coated on the core tablet by using HPMC as a barrier layer coat to avoid all 
possible interaction between Eudragit E100 and S100 since they are oppositely charged and 
different plasticizers PEG 400, Talc and PG were also used to give a proper coating and strength 
to the tablet. The coating of pH dependent polymers was done at three coating levels to give a 
net weight increase of about 3, 6 and 9% respectively.  The barrier layer coat with HPMC was 
done to a constant weight increase of about 5%. Thus the core tablets have three layers coating 
comprising Eudragit S100 as the outer coat, HPMC as the middle layer barrier coat and Eudragit 
E100 as the innermost coat Evaluation studies were performed which includes all the 
preformulation and post formulation studies. The core and coated tablets evaluation studies 
includes hardness, friability, weight variation, drug content, thickness test and weight gain after 
each successive coating. In vitro drug release study was done in USP type II Paddle apparatus in 
different pH media such as pH1.2 for two hours, pH7.4 for three hours and pH6.8 for nineteen 
hours to mimic the intestinal pH and transit time. Sampling was done in prescribed time limit 
and analyzed for drug content using UV spectrophotometer at 271nm wavelength for calculating 
the drug release. 
        Formulation F8 with 9% coating level of Eudragit S100 and 6% coating level of Eudragit 
E100 along with 5% HPMC barrier coating was found to be the optimized one as it showed more 
than 90% release in the colonic condition, with negligible release in the intestinal pH and it also 
gave a complete release in 24h. It can be concluded that, the combination of Eudragit E100 and 
S100 can be used effectively for colon targeting of drugs. Further animal studies for the in vivo 
results are necessary to claim complete success from the study. 
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1. INTRODUCTION 
                Modified release delivery systems are divided into four, namely, delayed release, 
sustained release, site-specific targeting and receptor targeting. Colon targeted drug delivery is 
an example of controlled drug delivery system. The most convenient route of administration of 
drugs to patients is reputed to be the oral route as against other routes. Upon administration of 
conventional dosage forms through the oral route they dissolve in the stomach or intestinal fluids 
from where the absorption of the active drug takes place. The kinetics of absorption of such 
dosage forms through the mucosal walls depends greatly on the physicochemical properties of 
the drug in question. Experience shows that conventional drug delivery is unfavorable to special 
cases where drug targeting is sought, that is, when avoidance of gastric dissolution or targeting to 
the colon is desirable. Colon targeted drug delivery differs from ordinary enteric coating (that are 
designed to merely avoid drug release in the stomach) in that the tablet or capsule is specially 
formulated to channel greater quantity of drug release to the colonic compartment, thus 
preventing or highly reducing drug release until the dosage form reaches the colon1 . 
 
                Colon has a longer retention time and appears to be highly responsive to agents that 
enhance the absorption of poorly absorbed drugs. A colon specific drug delivery system is 
required to protect the drug during its transit through the upper gastrointestinal tract and to allow 
its release in the colon. It is advantageous if drug release from a formulation can begin 
immediately after it enters the colon 2.Colon specific drug delivery systems are potential not only 
for delivering various drugs to combat the local diseases of colon such as crohn’s disease, 
ulcerative colitis, constipation and colon cancer but also for delivering some drugs for the 
systemic absorption for treating some diseases such as rheumatoid arthritis, nocturnal asthma, 
hypertension which possess circadian rhythms in their symptoms 3  
 
               Colon specific drug delivery systems (CoDDS) have been developing as one of the site-
specific drug delivery systems. Along with many applications in local and systemic delivery of 
drugs the CoDDS would also be advantageous when a delay in absorption is desirable from a 
therapeutic point of view as for the treatment of diseases that have peak symptoms in the early 
morning and that exhibit circadian rhythm, such as nocturnal asthma, angina and rheumatoid 
arthritis.  So by developing the pulsatile device for specific colonic delivery, plasma peak is 
20 
 
obtained at an optimal time, number of doses per day can be reduced, first pass metabolism and 
tolerance development can also be avoided 4 
 
1.1 Rationale for colon targeting 5, 6: 
 
Colon-specific drug delivery system offers the following therapeutic advantages; 
 
 Reducing the adverse effects in the treatment of colonic diseases (ulcerative colitis, 
colorectal cancer, crohn’s disease etc.) 
 By producing the ‘friendlier’ environment for peptides and proteins when compared to 
upper gastrointestinal tract. 
 Delayed release of drugs to treat early morning attacks of angina, asthma and rheumatoid 
arthritis  
 Reduced incidence of side effects and drug interactions. 
 Bypass initial first pass metabolism, extended daytime or nighttime activity. 
 Improve patient compliance. 
 It has a longer retention time and appears highly responsive to agents that enhance the 
absorption of poorly absorbed drugs 
 
1.2 limitations of colon targeting 7: 
 
 Location at distal portion of alimentary canal, the colon is difficult to access. 
 Successful delivery requires the drug to be in solution before it arrives in the colon, but 
fluid content in the colon is lower and more viscous than upper GIT, which is the 
limiting factor for poorly soluble drugs. 
 Lower surface area and tightness of light junctions in colon can restrict drug transport 
across mucosa into systemic circulation. 
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1.3 Anatomy and physiology of colon 8: 
            The GI tract is divided into stomach, small intestine and large intestine. The large 
intestine extending from the ileocecal junction to the anus is divided in to three main parts. These 
are the colon, the rectum and anal canal. The entire colon is about 5feet (150cm) long, and is 
divided in to five major segments. Peritoneal folds called as mesentery which is supported by 
ascending and descending colon. The right colon consists of the cecum, ascending colon, hepatic 
flexure and the right half of the transverse colon The left colon contain the left half of the 
transverse colon, descending colon, splenic flexure and sigmoid. The rectum is the last anatomic 
segment before the anus. 
 
            The major function of the colon is the creation of suitable environment for the growth of 
colonic microorganisms, storage reservoir of faecal contents, expulsion of the contents of the 
colon at an appropriate time and absorption of potassium and water from the lumen. The 
absorptive capacity is very high, about 2000ml of fluid enters the colon through the ileocecal 
valve from which more than 90% of the fluid is reabsorbed. On average, it has been estimated 
that colon contains only about 220gm of wet material equivalent to just 35gm of dry matter. The 
majority of this dry matter is bacteria. The colon tissue contains the villi, lymph, muscle, nerves, 
and vessels. 
 
1.3.1 Ascending colon 9: 
         The ascending colon is approximately 15cm long and joins the caecum at the ileocaecal 
junction. The ascending colon is covered with peritoneum anteriorly and on both sides, however, 
its posterior surface is devoid of peritoneum. It ascends on the right side of the abdomen to the 
level of the liver where it bends acutely to the left. At this point it forms the right colic or hepatic 
flexure and then continues as the transverse colon. 
 
1.3.2 Transverse colon: 
         This is a loop of colon approximately 45cm long that continues from the left hepatic 
flexure across to the left side of the abdomen to the left colic flexure. It passes in front of the 
stomach and duodenum and then curves beneath the lower part of the spleen on the left side as 
the left colic or splenic flexure and then passes acutely downward as the descending colon. 
22 
 
1.3.3 Descending colon: 
         This section of the colon passes downwards on the left side of the abdomen to the level of 
the iliac crest. It is approximately 25cm in length. The descending colon is narrower and more 
dorsally situated than the ascending colon. 
 
1.3.4 Sigmoid colon: 
        The sigmoid colon begins near the iliac crest and is approximately 36cm long. It ends at the 
centre of the mid-sacrum, where it becomes the rectum at about the level of the third sacral 
vertebra. It is mobile and is completely covered by peritoneum and attached to the pelvic walls in 
an inverted V shape. 
 
 
 
 
Fig 1: Human Intestinal Colon  
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Table 1: Summary of anatomical and physiological feature of small intestine and colon 10: 
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           The best Candidates for CoDDS are drugs which show poor absorption from the stomach 
or intestine including peptides. The drugs used in the treatment of IBD, ulcerative colitis, 
diarrhea, and colon cancer are ideal candidates for local colon delivery. The criteria for selection 
of drugs for CoDDS is summarized in this table 2  
 
Table 2: Criteria for selection of drug for CoDDS 11: 
 
CRITERIA PHARMACOLOGICAL 
CLASS 
NON-PEPTIDE 
DRUGS 
PEPTIDE DRUGS 
Drugs used for local 
effects in colon 
against GIT diseases 
 
Anti-inflammatory drugs 
 
Oxyprenolol, 
Metoprolol, Nifedipine 
 
Amylin, Antisense 
oligonucleotide 
 
Drugs poorly 
absorbed from upper 
GIT 
 
Antihypertensive and 
antianginal drugs 
 
Ibuprofen, Isosorbides, 
Theophylline 
 
Cyclosporine, 
Desmopressin 
 
Drugs for colon 
cancer 
 
Antineoplastic drugs 
 
Pseudoephedrine 
 
Epoetin, Glucagon 
 
Drugs that degrade in 
stomach and small 
intestine 
 
Peptides and proteins 
 
Bromophenaramine, 5-
Flourouracil, 
Doxorubicin 
 
Gonadoreline, Insulin, 
Interferons 
 
Drugs that undergo 
extensive first pass 
metabolism 
 
Nitroglycerin and 
corticosteroids 
 
Bleomycin, Nicotine 
 
Protirelin,sermorelin, 
Saloatonin 
 
Drugs for targeting Antiarthritic and 
antiasthamatic drugs 
Prednisolone, 
hydrocortisone, 
5-Amino-salicylic acid 
Somatropin,Urotoilitin 
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1.4 Colonic absorption of drug 7:  
           The surface area of colon is compensated by absence of endogenous digestive enzymes 
and long residence time of colon (10-24hours).transcellular absorption involves the passage of 
drug through the cells and thus the route for most lipophilic drugs, whereas paracellular 
absorption involves the transport of drug through the tight junction between the cells and thus the 
route for most hydrophilic drugs.  
 
1.4.1 Factors affecting colon absorption 12: 
 
 Passage through coloncytes(transcellular transport) 
 Passage through adjacent coloncytes(paracellular transport) 
 Physical properties of drug such as pKa and degree of ionization. 
 Colonic residence time as commanded by GIT motility. 
 Degradation by bacterial enzymes and metabolic products. 
 Local physiological action of drug. 
 Selective and non-selective binding to mucus. 
 Disease state. 
 
1.5 Advantages of CoDDS over conventional drug delivery 10, 13: 
 
 Chronic colitis, namely ulcerative colitis and cirrhosis disease are currently treated with 
glucocorticoids, and other anti-inflammatory agents. 
 Drugs are available directly at the target site. 
 Side effects can be reduced. 
 Utilization of drug is more. 
 Lesser amount of dose is required comparatively. 
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1.6 Factors to be considered in the design of colon-specific drug delivery 
system 14 
 
1.6.1 Colonic micro flora and their enzymes 14  
         Intestinal enzymes are used to trigger drug release in various parts of the GI tract. Usually 
these enzymes are derived from gut microflora residing in high numbers in the colon. These 
enzymes are used to degrade coatings/matrices as well as to break bonds between an inert carrier 
and an active agent (i.e. release of a drug from a prodrug). Over 400 distinct bacterial species 
have been found, 20% to 30% of which are of the genus Bacteroides. The upper region of the GI 
tract has a very small number of bacteria and predominantly consists of Gram-positive 
facultative bacteria. The concentration of bacteria in the human colon is 1011 to 1012 CFU/ml. 
The most important anaerobic bacteria are Bacteroides, Bifidobacterium, Eubacterium, 
Peptococcus, Peptostreptococcus, Ruminococcus, Propionibacterium, and Clostridium.20 a 
summary of the most important metabolic reactions carried out by intestinal bacteria is provided 
in Table.3 
 
Table 3: Metabolic reactions carried out by intestinal bacteria: 
 
 
 
 
Enzymes Microorganism Metabolic reaction catalyzed 
Nitroreductase E. coli, Bacteroides Reduce aromatic and 
heterocyclic nitro compounds 
Azoreductase Clostridia, Lactobacilli, E. coli Reductive cleavage of azo 
compounds 
Esterase and amidases E. coli, P. vulgaris, B. subtilis, 
B. mycoides 
Cleavage of esters or amidases 
of carboxylic acids 
Glycosidase Clostridia, Eubacterium Cleavage of β-glycosidase of 
alcohols and phenols 
Glucuronidase E. coli, A. aerogenes Cleavage of β-glucuronidases 
of alcohols and phenols 
27 
 
1.6.2 pH in the Colon15: 
         The average pH of the caecum and colon lumen is 6.8 ± 0.85. The highest pH levels (7.5 ± 
0.5) were found in the terminal ileum. On entry into the colon, the pH dropped to 6.4 ± 0.6. The 
pH in the mid-colon was measured at 6.6 ± 0.8 and in the left colon, 7.0 ± 0.7. The fall in pH on 
entry into the colon is due to the presence of short chain fatty acids arising from the bacterial 
fermentation of polysaccharides for example, lactose is fermented by colonic bacteria to produce 
large amounts of lactic acid, resulting in a drop in the pH to about 5.0. Colonic pH has been 
shown to be reduced in disease like ulcerative colitis. Diet, diseased state, and food intake 
influence the pH of the gastrointestinal fluid. 
 
1.6.3 Gastrointestinal transit 16  
          The gastric emptying of dosage form is highly variable and depends primarily on whether the 
subject is fed or fasted and the property of dosages form (such as size and density). The mean transit 
time from mouth to anus is 53.3hrs. The total mean colonic transit time is 25.0 hrs and is shorter in 
males than females. The effect of transit abnormalities has been examined using gamma 
scintigraphy in which oral administration of a radiolabelled liquid meal to patients takes place. 
Transit time of dosage form in GIT is given in Table-4 
 
 
 
Table 4: Transit time of dosage form in GIT 
 
 
  
 
 
 
 
Organ Transit time (hr) 
Stomach <1 (Fasting) >3 (Fed) 
Small intestine 3-4 
Large intestine 20-30 
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1.7 Approaches for colonic drug delivery 17 
 
 [A]- Primary approaches for CoDDS 
 
(a) Microbially triggered drug delivery to colon. 
 
          (i) Prodrug approach 
          (ii) Azo bond conjugate  
          (iii) Polysaccharide based approach 
 
      b) Delayed release or Time controlled release system 
      c) pH sensitive systems 
 
 
[B]- Newly developed approaches for CoDDS 
 
       a) Pressure controlled drug delivery system (PCDDS) 
       b) Osmotic controlled drug delivery to colon (OROS-CT) 
       c) CODESTM (a novel colon targeted delivery system) 
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[A]- Primary approaches for CoDDS 
 
a) Microbially triggered drug delivery to colon 18- 22. 
 
       When the dosage form passes through the GIT, it remains intact in the stomach and small 
Intestine where very little microbial degradable activity is present which is insufficient for 
cleavage of the polymer coating. The microflora of colon is in the range of 1011 -1012 CFU/mL, 
consisting mainly of anaerobic bacteria, e.g. Bacteroides, Bifidobacteria, Eubacteria, Clostridia, 
Enterococci, Enterobacteria and Ruminococcus etc. This vast microflora fulfills its energy needs 
by fermenting various types of substrates that have been left undigested in the small intestine, 
e.g. di- and tri-saccharides, polysaccharides etc 20. For this fermentation the microflora produces 
a vast number of enzymes like glucoronidase, xylosidase, arabinosidase, galactosidase, 
nitroreductase, azareducatase, deaminase, and urea dehydroxylase. Because of the presence of 
the biodegradable enzymes only in the colon, the use of biodegradable polymers for colon-
specific drug delivery seems to be a more site-specific. These polymers shield the drug from the 
environments of stomach and small intestine and are able to deliver the drug to the colon. On 
reaching the colon, they undergo assimilation by micro-organism or degradation by enzyme or 
break down of the polymer back bone leading to a subsequent reduction in their molecular 
weight and thereby loss of mechanical strength.  
 
Fig 2: Concentration of bacterial flora in different regions of GIT  
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Fig 3: Human intestinal microflora distribution in number (log 10) per gram faeces 
 
 
 
(i) Prodrug approach 23, 24: 
 
           Prodrugs have been used in targeting drugs to the colon. Prodrugs are designed to undergo 
minimal absorption and hydrolysis in the tracts of upper GIT and undergo enzymatic hydrolysis 
in the colon, there by releasing the active drug moiety from the drug carrier. Subsynthetic 
polymers have been used to form polymeric prodrug with azo linkage between the polymer and 
drug moiety. The list of different prodrug is given in table 5. 
               SASP is the classic colon specific prodrug originally discovered in the late 1930’s by 
the Scandinavian physician Dr. Nanna svartz 26 
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Fig 4: The chemical structure of SASP, Balsalazide, Ipsalazide, and OSZ showing the site 
of bacterial cleavage leading to formation of active agent 5-asa 
(SASP-salicylazasulfapyridine (sulfasalazin) 
OSZ-osalazine) 
 
Table 5: Prodrugs evaluated for colon-specific drug delivery 38 
 
Drug investigated 
 
 
Carrier Linkage hydrolyzed 
5-ASA 
 
 
Azo conjugates 
sulphapyridine(SP) 
Azo linkage 
5-ASA 
 
 
5-ASA Azo linkage 
Dexamethasone/ Prednisolone 
 
 
Saccharide carriers Glycosidic linkage 
Dexamethasone; Prednisolone 
Hydrocortisone,Fludrocortisone 
 
Glucose/galactose/cellobioside Glycosidic linkage 
Nalaxone/Nalamefene 
 
 
Glucoronide conjugates 
Glucoronic acid 
Glucuronide linkage 
Salicylic acid 
 
 
Amino acid conjugates 
glycine 
Amide linkage 
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(ii) Azo bond conjugate18 
 
          These azo compounds are extensively metabolized by the intestinal bacteria, both by 
intracellular enzymatic component and extracellular reduction. Newer approaches are aimed at 
use of polymers as drug carriers for drug delivery to the colon. Both synthetic as well as 
naturally occurring polymers are used for this purpose. Subsynthetic polymers have been used to 
form polymeric prodrug with azo linkage between the polymer and drug moiety. These have 
been evaluated for CoDDS; various azo polymers have also been evaluated as coating materials 
over drug cores. These have been found to be similarly susceptible to cleavage by the 
azoreductase in the large bowel. Coating of peptide capsules with polymers cross linked with 
azoaromatic group has been found to protect drug from digestion in the stomach and small 
intestine. In the colon the azo bonds are reduced and the drug is released. 
 
 
(iii) Polysaccharides based systems25 
 
           Polysaccharides are the polymers of monosaccharides which retains their integrity 
because they are resistant to the digestive action of gastrointestinal enzymes. The matrices of 
polysaccharides are assumed to remain intact in the physiological environment of stomach and 
small intestine; however, they are acted upon by the bacterial polysaccharidases once they reach 
in the colon resulting in the degradation of the matrices. Natural polysaccharide polymers have 
an appeal to the area of drug delivery as they are comprised of polymers having a large number 
of derivatizable groups, a wide range of molecular weights, biodegradability, varying chemical 
compositions, a low toxicity yet high stability. They are already approved as pharmaceutical 
excipient. The number of polysaccharides such as amylose, guar gum, pectin, chitosan, inulin, 
cyclodextrins, chondroitin sulphate, dextrans and locust bean gum has been investigated for their 
use in colon targeted drug delivery systems. The selection of a suitable biodegradable 
polysaccharide is the most important factor in the development of polysaccharide derivatives for 
colon targeted drug delivery. 
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Table 6: Polysaccharides investigated for colon-specific drug delivery 38 
 
 
 
b) Delayed release or Time controlled release system 27: 
                    Sustained release dosage forms are designed to prolong drug dissolution and hence 
absorption. These formulations move down the GIT at rates dependent on their location as drug 
is released from the formulation as it passes down the gut, it is absorbed at a rate depending on 
the drug’s permeability properties and other factors. Unabsorbed drug or drug not released from 
the formulation is excreted in the faeces. Although less sophisticated than other approaches to 
targeting drug release in the GI tract, simple sustained release systems are used to deliver drugs 
to various sites. Sustained release is the basis of Pentasa R (mesalamine) 27, which relies on 
ethylcellulose-coated beads to slowly release mesalamine (5-aminosalicylic acid, 5-ASA) as they 
pass down the GIT. It is indicated for treatment of UC; despite the fact inflammation is located in 
the distal intestine. The relative bioavailability of mesalamine from this formulation is low. If 
mesalamine is released from the formulation but unabsorbed, it can still reach the inflamed 
mucosa and possibly exert a local anti-inflammatory effect. Following gastric emptying, transit 
through the small bowel is relatively consistent at 3±1 h. Thus, it is possible to exploit small 
intestinal transit times to control the site of drug release. Since gastric residence times are often 
Polysaccharide investigated  
 
Drug moiety used  Dosage form prepared  
Chitosan  Sodium diclofenac  Enteric-coated chitosan  
microspheres  
Amidated pectin  
 
Paracetamol  Matrix tablets  
Amidated pectin  Indomethacin  
Sulphamethoxazole  
Chitosan-coated amidated 
pectin beads  
pH-sensitive dextran  Bovine serum albumin (BSA)  As hydrogels  
 
Amidated pectin  
 
Ropivacaine  Matrix tablet  
Locust bean gum  
 
Theophylline  Film  
Dextran fatty acid esters  
(Degree of substitution 20.12–
0.40)  
Theophylline  As films  
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variable and dependent on the presence or absence of food, enteric polymers are used to delay 
release until the formulation reaches the proximal small intestine. Thus, a dual mechanism is 
used to delay release until the dosage form reaches the lower intestine. 
 
c) pH sensitive system7,40,41: 
 
            pH dependent coatings make possible the design of dosage forms containing high levels 
of drugs, as alternatives to matrix or hydrogel systems: using polymers dissolving at pH> 7 for 
e.g. Eudragit (41) it is possible to prevent tablets or pellets from releasing drugs in the stomach or 
proximal small intestine in stomach pH ranges between 1-2during fasting but increases after 
eating. The pH is 6.5 in proximal small intestine and about 7.5 in distal small intestine from 
ileum to colon pH declines significantly. It is about 6.4 in the caecum. pH values as low as 5.7 
have been measured in ascending colon in healthy volunteers. The pH in the transverse colon is 
6.6 in descending colon 7.0 use of pH dependent polymers is based on these differences in pH 
levels. The polymers described as pH dependent in colon specific drug delivery are insoluble at 
low pH levels but become increasingly soluble as pH rises. Although a pH depend polymer can 
protect a formulation in stomach and proximal small intestine. It may start to dissolve even in 
lower small intestine and the site specificity of the formulation can be poor. Enteric coated 
dosage forms are designed to remain intact in the stomach and release the active substances in 
intestine. pH sensitive coating can be used to deliver the drug to the colon. Unit dosage forms 
and multiparticulate dosage forms have been coated with pH dependent polymers to provide site 
specific release. 
 
 
[B]- Newly developed approaches for CoDDS  
 
(a) Pressure controlled drug delivery system (PCDDS) 28, 39: 
 
            The digestive processes within the GI tract involve contractile activity of the stomach and 
peristaltic movements for propulsion of intestinal contents. In the large intestine, the contents are 
moved from one part to the next, as from the ascending to the transverse colon by forcible 
peristaltic movements commonly termed as mass peristalsis. These strong peristaltic waves in 
the colon are of short duration, occurring only three to four times a day. However, they 
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temporarily increase the luminal pressure within the colon, which forms the basis for design of 
pressure-controlled systems. The use of gastrointestinal pressure has been proposed as a method 
of targeting release in the distal gut. This pressure which is generated via muscular contractions 
of the intestinal wall for grinding and propulsion of luminal contents varies in intensity and 
duration throughout the gastrointestinal tract. The colon is believed to exert a higher effective 
luminal pressure via the action of haustral contractions coupled with a viscous environment. This 
pressure controlled colon delivery capsule (PCDC) is composed of drug, dispersed in a 
suppository base, coated with the water insoluble polymer ethyl cellulose. Once swallowed, the 
temperature of the body causes the suppository base to melt and increase in volume, and the 
system resembles a liquid filled ethyl cellulose balloon. The system is able to withstand the 
luminal pressures of the stomach and small intestine resulting from muscular con- traction of the 
gut wall, since there is sufficient fluid present in the lumen to dissipate this pressure. In the distal 
gut, reabsorption of water increases the viscosity of luminal contents. As such, the capsule will 
be directly affected when subjected to the pressure of the intense haustral contractions of the 
colon and hence will rupture. The use of gastrointestinal pressure provides an innovative 
approach to targeting drugs to the gut.  
 
(b) Osmotic controlled drug delivery to colon (OROS-CT) 29,43 
 
          Linkwitz et al 42 invented an osmotic drug (single unit) delivery capsule from which the 
delivery of the drug was driven by the osmotic infusion of the moisture by the capsule from a 
physiological environment. It was provided with a delivery orifice that opened intermittently to 
achieve a pulsatile delivery effect. The technology involves a movable position that divides the 
capsule interior into two compartments- one for the beneficial agent and the other for the 
osmotically active agent. The orifice is located on the capsule wall surrounding the beneficial 
agent side. The whole capsule is surrounded by an elastic wall in the osmotically active 
compartment due to inward diffusion of water, which is transmitted through the partition. When 
the pressure in the drug compartment exceeds the threshold, it results in opening of the orifice 
and as a result, an amount of beneficial agent is released and it relieves the pressure in the drug 
compartment. This release in pressure causes the elastic material to relax and results in closures 
of the orifice. There are various factors affecting the degree and manner in which the pulsatile 
effect can be controlled, like the choice of elastic material, the thickness of the wall section, the 
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configuration and location of the orifice and the viscosity and surface tension of the beneficial 
agent formulation. The choice of elastic material is done on the ability to stretch at least twice 
their original length and to retract very rapidly when released. 
 
 
 
 
Fig 5: Osmotic drug delivery system 
 
 
 
(c)  CODESTM (a novel colon targeted delivery system) 29, 30: 
 
         CODES™ is a unique colon-specific drug delivery technology that was designed to avoid 
the inherent problems associated with pH- or time-dependent systems. The design of CODES™ 
exploited the advantages of certain polysaccharides that are only degraded by bacteria available 
in the colon. This is coupled with a pH-sensitive polymer coating. Since the degradation of 
polysaccharides occurred only in the colon, this system exhibited the capability to achieve colon 
delivery consistently and reliably. As schematically presented in Fig.5 typical configuration of 
CODES™ consists of a core tablet coated with three layers of polymer coatings. The first 
coating (next to the core tablet) is an acid-soluble polymer (in the present case, Eudragit E was 
used) and outer coating is enteric with a HPMC barrier layer in between to prevent any possible 
interactions between the oppositely charged polymers.The core tablet is comprised of the active, 
one or more polysaccharides and other desirable excipients. The polysaccharides, degradable by 
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enterobacteria to generate organic acid, include mannitol, maltose, stachyose, lactulose, 
fructooligosaccharide etc. During its transit through the GI tract, CODES™ remains intact in the 
stomach due to the enteric protection, but the enteric and barrier coating will dissolve in the 
small intestine, where the pH is above 6. Because Eudragit E starts to dissolve at pH5, the inner 
Eudragit E coating is only slightly permeable and swellable in small intestine. Upon entry into 
the colon, the polysaccharide inside the core tablet will dissolve and diffuse through the coating. 
The bacteria will enzymatically degrade the polysaccharide into organic acid. This lowers the pH 
surrounding the system sufficient to affect the dissolution of the acid-soluble coating and 
subsequent drug release. 
 
 
 
 
 
Fig 6: Schematics of the conceptual design of CODES™ 
 
 
 
38 
 
 
 
 
Fig 7: Schematics of the conceptual design of CODES™ 
 
 
39 
 
 
 
Fig 8: Behavior of Eudragit polymers in digestive tract 
 
The CoDDS can be used as an efficient dosage form to deliver the drugs to the colon for 
effective treatment of local or systemic disease of colon and for the timed delivery of drugs in 
case of disease following circadian rhythm. 
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Plan of Work 
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OBJECTIVE AND PLAN OF WORK 
 
OBJECTIVE 
To formulate and evaluate colon targeted drug delivery system of Tramadol hydrochloride by 
using different polymers such as Eudragit E100, HPMC, and Eudragit S100.   
 
PLAN OF WORK 
 To determine the λ max of the drug and construct the calibration curve  
 To conduct the preformulation studies 
 To formulate colon targeted drug delivery system 
 To carry out physical evaluation tests 
 To carry out the In vitro dissolution studies 
 To determine the effect of formulation parameters on dissolution 
 Determination of release kinetics. 
 Stability studies. 
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LITERATURE REVIEW 
 
Patel T.D. et al 52 has investigated the development of delayed release (DR) tablet of 
Mesalazine, where Lactose-based placebo tablets were coated using methacrylic acid copolymers 
Eudragit S100 by spraying from aqueous and organic system & Instacoat IEN-II-218 by spraying 
from organic system. The Dissolution studies performed on the mesalazine tablets demonstrated 
that a Eudragit S100 can be successfully used for aqueous & organic system to coat tablets for 
colon targeted delivery of drug. Among the ten formulations, F9 best matched formulation with 
respect to market product. Optimized formulation was found stable during accelerated stability 
study for 3 months at 40
0
C/75% RH. It is concluded that Eudragit S100 far more superior than 
Instacoat IEN-II-218. 
 
S. J. Kshirsagar et al 53 developed the polymer coated Diclofenac tablet Eudragit FS 3D and 
Eudragit S100 were used as pH sensitive polymers. Tablets were coated separately with Eudragit 
FS 30D and Eudragit S100 in various thicknesses and evaluated for in vitro drug release using 
changing pH method. In vitro release studies reveals that Eudragit FS30D coated tablet with 
10%w/w coating level start release of drug at pH 6.8 after suitable lag time in the same pH which 
corresponds to colonic arrival time, as compare to Eudragit S100 coated tablet which release 
only at higher pH , approximating the transverse colon. In vivo study shows that Tablet coated 
with EudragitFS30D with 10%w/w coating level and Eudragit S100 with 10% coating level 
disintegrated in cecum region. Thus Eudragit FS30D coated tablet may be a promising system 
for the treatment of colonic disease  
 
Gang Cheng et al 54 has investigated Time- and pH-dependent colon-specific drug delivery 
systems (CoDDS) for orally administered diclofenac sodium (DS) and 5-aminosalicylic acid (5-
ASA), respectively by using Ethylcellulose (EC) and methacrylic acid copolymers (Eudragit 
L100 and S100), respectively as coating polymer. The in vitro release behavior of the DS coated 
tablets and 5-ASA coated pellets were examined, and then in vivo absorption kinetics of DS 
coated tablets in dogs were further studied. Result was demonstrated that thicker the coating 
layer, longer the lag time of DS release. The absorption kinetic studies in dogs demonstrated that 
in vivo lag time of absorption was in a good agreement with in vitro lag time of release. 
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Varshosaz J. et al 55 has studied the development of Budesonide pellets based on colon drug 
delivery system (CODESTM). In this  Pellets cores containing lactulose or mannitol were 
prepared by extrusion/spheronization and coated with an acid soluble polymer (Eudragit E100), 
Hydroxypropylmethyl cellulose (HPMC) and an enteric coat (Eudragit FS 30D) sequentially.    
In vitro drug release of coated pellets was studied using USP dissolution apparatus type II in 
buffers of pH 1.2 (2 hrs), pH of 7.4 (4 hrs) and pH of 6.8 containing 8% rat cecal contents (RCC) 
(18 hrs). The efficacy of the optimized formulation (containing 50% lactulose coated with 
Eudragit E (30% w/w) and Eudragit FS 30D (12% w/w)) was evaluated against 2, 4, 6-
trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats. 
 
Hangargekar Sachin et al 56 has formulated colon targeted tablets of Secnidazole with Xanthan 
gum as matrix carrier. Initially granules were prepared and evaluated for various rheological 
characteristic. In vitro release study was conducted for all formulations in USP XXIV 24 type I 
basket apparatus in different pH medias as follows, the tablets were put in the jars containing 900 
ml of dissolution medium was stirred at 100 rpm at 37±0.50 C for first 2 hour jar was filled with 
pH 1.2 dissolution fluid after 2 hour jar was filled with pH 7.4 for a period of 5 hour further jar 
assembly was lifted and dissolution fluid was replaced with pH 6.8 for a period of 24 hours, 
Samples were collected at the 1 hour time interval and studied for absorbance. Results were 
concluded that the formulations containing 25% w/w Xanthan gum showed maximum drug 
release in colonic environment. 
 
Jinhe Li et al 57 has studied Dissolution Behavior for a Colon-Specific Drug Delivery System 
(CODES™) in Multi-pH Media using acetaminophen (APAP) as a model drug. Release profiles 
in artificial gastric fluid (pH 1.2), intestinal fluid (pH 6.8), and pH 5.0 buffer were determined. 
As expected, the percent release of APAP from coated core tablets was highly pH dependent. A 
release profile exhibiting a negligible release in pH 1.2 and 6.8 buffers followed by a rapid 
release in pH 5.0 buffer was established. It was interesting to note that there was a close 
similarity (f2 = 80.6) between the release profiles at dip speed 5 dpm and paddle speed 100 rpm. 
In addition, the release rate was reduced significantly with the increase in acid-soluble Eudragit 
E coating levels, but lactulose loading showed only a negligible effect. In conclusion, the 
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established reciprocating cylinder method at lower agitation rates can give release profiles 
equivalent to those for the paddle procedure for CODES™ drug pH-gradient release testing 
 
M. Zahirul I. Khan et al 58 has investigated lactose-based placebo tablets coated with various 
combinations of two methacrylic acid copolymers, EudragitL100-55 and EudragitS100, by 
spraying from aqueous systems. The Eudragit L100-55 EudragitS100 combinations (w/w) 
studied were 1:0, 4:1, 3:2, 1:1, 2:3, 1:4, 1:5 and 0:1. The coated tablets were tested in vitro for 
their suitability for pH dependent colon targeted oral drug delivery. The same coating 
formulations were then applied on tablets containing mesalazine as a model drug and evaluated 
for in vitro dissolution rates under various conditions. Dissolution studies performed on the 
mesalazine tablets further confirmed that the release profiles of the drug could be manipulated by 
changing the Eudragit L100-55 and Eudragit S100 ratios within the pH range of 5.5 to 7.0 in 
which the individual polymers are soluble respectively, and a coating formulation consisting of a 
combination of the two copolymers can overcome the issue of high gastrointestinal (GI) pH 
variability among individuals. The results also demonstrated that a combination of Eudragit 
L100-55 and Eudragit S100 can be successfully used from aqueous system to coat tablets for 
colon targeted delivery  
 
Manish Neekhra et al 59 has investigated the fabrication of the novel colon drug delivery system 
of ketorolac tromethamine capsule. Hard gelatin Capsules were fabricated using combination of 
both microflora activated natural polysaccharide (guar gum) and pH-dependent polymer 
(cellulose acetate phthalate). In vitro drug release studies revealed that Ketorolac tromethamine 
granules bearing hard gelatin capsules coated with cellulose acetate phthalate released drug only 
at higher pH (6.8 PBS), in vitro drug release studies showed that capsules were retained in 
stomach pH (1.2 N HCl) with-out any drug release, whereas minimal amount of drug release in 
small intestine pH (7.4 PBS) and almost complete drug release showed in the colonic pH (6.8 
PBS). 
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Lanjhiyana S.K et al 60 has investigated that the colon is an effective drug delivery site for local 
colorectal cancer treatment using 5-Fluorouracil (5-FU) as model drug based on oral pulsatile 
release technology. Formulations coated with enteric Eudragit-S100 and swellable hydroxyl 
propyl methyl cellulose (HPMC) to a varying coat thickness of 2:4, 4:2, 3:4 and 4:3, were tested 
for in-vitro drug dissolution with various simulated fluids of stomach (pH 1.2), small intestine 
(pH 7.2) and colon (pH 6.8 The optimized enteric coated formulations containing 30% guar gum 
released only 5-12% approximately of 5-FU during 5 h dissolution studies in hostile 
physiological environment of stomach (pH 1.2) and small intestine (pH 7.2).  
 
Francesca Maestrelli et al 61 has studied the Enteric-coated calcium pectinate microspheres 
(MS) aimed for colon drug delivery has been developed, by using theophylline as a model drug. 
Enteric coating with Eudragit S100 enabled maintenance of MS integrity until its expected 
arrival to colon. Unexpectedly, addition of pectinolytic enzymes to the colonic medium did not 
give rise to selective enzymatic degradation of MS. Notwithstanding this unforeseen result, 
coated MS prepared at 2.5% w/v CaCl2 concentration were able to adequately modulate drug 
release through a mixed approach of pH and transit time control, avoiding drug release in the 
gastric ambient, and reaching the colonic targeting where 100% release was achieved within less 
than 24 h. 
 
Soravoot Rujivipat and Roland Bodmeier 62 has developed pH-erosion-controlled 
compression-coated tablets for potential colonic drug delivery based on compression-coatings of 
powder blends of the enteric polymer Eudragit L100-55 and the extended release polymer 
Ethylcellulose. Tablet cores containing model drugs of varying solubility’s (Acetaminophen, 
Carbamazepine and Chlorpheniramine maleate) were compression coated with different ratios of 
Eudragit L100-55: Ethylcellulose 10cP FP. All drugs were released in a pulsatile fashion in 
higher pH-media after a lag time, which was controlled by the erosion properties of the Eudragit 
L: Ethylcellulose compression-coating. In conclusion, tablets compression-coated with blends of 
Eudragit L and Ethylcellulose resulted in excellent release properties for potential targeting to 
the lower intestinal tract with no release in lower pH-media and rapid release after a controllable 
lag time in higher pH-media. 
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Takashi Ishibashi et al 63 have investigated a new capsule-type dosage form for colon-targeted 
delivery of drugs. The system was designed by imparting a timed-release function and a pH-
sensing function to a hard gelatin capsule coated with a three-layered film consisting of an acid-
soluble polymer, a water-soluble polymer, and an enteric polymer. In order to find the suitable 
formulation, various formulation factors were investigated through a series of in vitro dissolution 
studies. As a result, it was found that: (1) various organic acids can be used for this system; (2) a 
predictable timed-release mechanism of a drug can be attained by adjusting the thickness of the 
Eudragit E layer; and (3) the outer enteric coating with HPMC®-AS provided acceptable acid-
resistibility. All these results suggested that this approach can provide a useful and practical 
means for colon-targeted delivery of drugs. 
 
Xiaxia Shen et al 64 developed Eudragit L 100-55 nanofibers loaded with diclofenac sodium 
(DS) were successfully prepared using an electrospinning process, and characterized for 
structural and pharmacodynamic properties. The influence of solvent and drug content on fiber 
formation and quality was also investigated. Fiber formation was successful using a solvent 
mixture 5:1 (v/v) ethanol: DMAc. XRD and DSC analysis of fibers confirm electron microscopic 
evidence that DS is evenly distributed in the nanofibers in an amorphous state. FTIR analysis 
indicates hydrogen bonding occurs between the drug and the polymer, which accounts for the 
molecular integration of the two components. In vitro dissolution tests verified that all the drug-
loaded Eudragit L 100-55 nanofibers had pH-dependent drug release profiles, with limited, less 
than 3%, release at pH 1.0, but a sustained and complete release at pH 6.8. This profile of 
properties indicates drug-loaded Eudragit L 100-55 nanofibers have the potential to be developed 
as oral colon-targeted drug delivery systems. 
 
R.Thiruganesh et al 65 has developed a single unit, site-specific matrix tablets of Aceclofenac 
allowing targeted drug release in the colon with a microbially degradable polymeric carrier, 
Chondroitin Suphate (CS) and to coat the optimized batches with a pH dependent polymeric 
coating solution containing Eudragit L 100 and S 100 (1: 4). The tablets were prepared by wet 
granulation using starch mucilage as a binding agent and HPMC K-100 as a swellable polymer. 
The tablets were tested for their in-vitro dissolution characteristics in various simulated gastric 
fluids for their suitability as a colon-specific drug delivery system. The dissolution data 
demonstrates that the 10% w/w increase in coating level of the pH dependent polymer (Eudragit 
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L-100 and Eudragit S-100 in a ratio of 1: 4 prevented the drug release in the simulated gastric 
fluid (pH 1.2-SGF) and the simulated intestinal fluid (pH 7.4-SIF).  
 
Purushothaman M and Vijay Ratna.J 66 has investigated the matrix formulations taken for 
compression and spray coating to test the suitability for targeted drug delivery to the colon. The 
release kinetics of the formulations was calculated. All the Matrix, Compression coated and 
Spray coated formulations were showed the desired physicochemical properties as per the 
official limits. Based on the drug release study in pH 1.2 (0.1N HCl), Phosphate buffer pH 7.4 
and 6.8, the three TGT F8, TGTE F20, and TGTES F32 were found to be best and they were 
taken for further release study in phosphate buffer pH 6.8 with rat cecal content (4% w/v). The 
formulations TGTE F20 ((r2 - 0.9986, n - 1.0601) and TGTES F32 (r2 -0.9974, n - 1.1501) were 
shown zero order release in terms of its kinetic release.  
 
Mayur M. Patel et al 67 investigated the colon specific drug delivery system (CDDS) which is 
designed such that the innermost part consists of a core tablet of mesalamine which is then 
compression coated with a pH-independent hydrophilic polymer (Hydropropylmethyl cellulose). 
This is then coated with a pH-dependent methacrylic acid copolymer (Eudragit® S100). The 
concentration (coating level) of Eudragit® S100 was optimized to provide an enteric coat that 
allows the tablet to pass intact through the stomach and is targeted to the colon. The coating 
thickness and grades of HPMC were optimized to set a desired lag time in the intestine. From the 
in vitro evaluation it can revealed that the developed CDDS can exhibit site-specific drug 
targeting to the colon. 
 
Mohanad naji sahib68 formulated prednisolone as an oral modified release tablet for colonic 
targeting. The formula containing 1% Eudragit RS PM was the best with regard to 100% release 
of drug in comparison with other concentrations and other retardant types. Avicel was used as a 
canalizing agent, and the results showed that the formula containing 30% Avicel PH 302 
demonstrated faster release. Eudragit S 100 provided the best release of drug in phosphate buffer, 
pH 7.4. The effect of the percent of binding agent polyvinylpyrrolidone (PVP) (5%, 10%, and 
15%) was studied, and the best results were obtained with a concentration of 10%. The trials in 
this study successfully formulated prednisolone-modified release tablets (coated matrix) using a 
wet granulation method as a potential colon delivery syst 
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Obitte NC et al 69 has evaluated the in vitro effect of, the percentage of surface area of capsule 
surface coated with Landolphia owariensis latex (LOL), particle size of granules, and %w/w of 
matrix former (methylcellulose) on the release of Metronidazole from coated hard gelatin 
capsules for possible delivery to the colon. Metronidazole granules were prepared by the wet 
granulation technique and appropriately encapsulated prior to primary coating of capsule with 
Eudragit® L-100 and secondary coating with LOL. Capsules having primary coating of 
Eudragit® L- 100 were coated with LOL atop 50% or 85% capsule surface. In vitro drug release 
was carried out sequentially in media of pH 1.2(0.1N HCl), 6.8 and 7.4(phosphate buffer 
solution) respectively. Results showed that the greatest quantity of drug release took place at pH 
7.4 at 20 h 
 
Sheth Zankhana et al 70  presented that  improvement in the efficacy, reduction in toxicity and 
enhancement of therapeutic index of 5-fluorouracil.Biodegradable microparticulate delivery 
system of 5-fluorouracil has been developed by solvent evaporation technique by using 
polymethacrylate polymers like eudragit L100, eudragit S100, eudragit P4135F and 
methylcellulose. Four different formulations were prepared by using these polymers in drug to 
polymer ratio of 1:2. The formulations were evaluated with respect to particle size analysis, 
entrapment efficiency, in vitro drug release studies, in vivo drug targeting studies and stability 
studies. The formulated magnetic microspheres were found to be spherical with average particle 
size of 3-12 µm in diameter and incorporation efficiency up to 78.80%. In vitro drug release after 
12 hr was 86.41 %, 92.84 %, 79.88 % and 82.38 % for formulation F1, F2, F3 and F4 
respectively. Formulation F2 with highest drug content was selected for in-vivo drug targeting 
studies. The average targeting efficiency of drug loaded microspheres was found to be 26.16 % 
of the injected dose in liver, 11.40 % in lungs, and 15.08 % in spleen, whereas the concentration 
of pure drug was 15.52 % in liver, 9.0 % in lungs, and 9.50 % in spleen. These results reveal that 
the drug loaded microspheres showed preferential drug targeting to liver followed by spleen and 
lungs. Stability studies revealed that 4º C is the most suitable temperature for storage of 5 - 
fluorouracil loaded microspheres. Overall, this study showed that the 5 - fluorouracil can be 
formulated in a microparticulate drug delivery system by using various polymers and it showed 
significant prolonged drug release. 
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Jatin A Popat 71 presented that the core tablets of Salbutamol Sulphate were prepared using wet 
granulation containing a superdisintegrant. Eudragit S100 and Eudragit L100 were used as pH 
dependent polymers for coating the core tablet which were filled in to the capsule. The ratio of 
Eudragit S100 and Eudragit L100 and the coating level was optimized using 32 full factorial 
designs. Factors studied in design were percentage of Eudragit S100 in combination with 
Eudragit L100 and the effect of coating level on In-vitro drug release. Dissolution studies at 
different pH (1.2, 5.5, 6.8 and 7.4) showed that drug release in colon could be modulated by 
optimizing the concentration of Eudragit L100: Eudragit S100 (1:2). The study showed that, lag 
time prior to drug release was highly affected by the coating level. The dissolution data revealed 
that the level of coating and the ratio of polymers are very important to achieve a optimum 
formulation.  
 
Gauri Bhawna et al 72 has developed the Matrix system of Tinidazole by using swellable pH 
dependent polymer like Hydroxypropylmethylcellulose (HPMC-K4M) and guar gum and 
methacrylic acid polymers like Eudragit FS 30D. Prepared tablets were compression coated in 
order to overcome variability in gastric emptying time and delay in release, to reduce the gastric 
side effects and to provide prolonged localized action in colon. The coated formulations were 
evaluated for dissolution rates under stomach and simulated intestinal conditions in presence of 
rat cecal content medium. In-vivo gamma scintigraphy study was also performed on (F3) 
formulation in healthy human volunteers using Tc-99m as a tracer medium. In-vitro drug release 
studies and In-vivo gamma-scintigraphic studies using Tc-99m as a tracer indicated that greater 
portion of Tinidazole was released in the large intestine and drug level was maintained in blood 
for 20h.  
 
Upendra Nagaich et al 73 has developed the colon specific sustained release matrix tablets of an 
antifilarial drug diethylcarbamazine citrate (DEC). The colon targeted matrix tablet was prepared 
by wet granulation technique using different percentage of guar gum as matrix carrier and coated 
with Eudragit L-100. The dissolution study of DEC matrix tablet was performed in simulated 
colonic fluids (phosphate buffer pH 6.8) was found to be 94% and in simulated colonic fluids 
(rat caecal content medium) was 98% after degradation into 2-3 pieces at the end of the 24 h 
study. The result of the studies showed that colon targeted matrix tablet containing 45% of guar 
gum was most likely to provide targeting of DEC for local action in the colon. The colon 
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targeted matrix tablet of DEC showed no change either in physical appearance, drug content or 
in dissolution pattern after storage at 300± 20C / 65 ± 5% RH for 2 month. FT-IR spectrum 
showed no interaction between DEC and guar gum. 
  
Rupesh S. Kamble 74 has preseted that Ketorolac Tromethamine direct compression method was 
used for the preparation of fabricated batches and EudragitL100 is used as coating polymer for 
enteric coating. In vitro release profiles of batches F1-F4 shows that Ketorolac Tromethamine in 
drug polymer ratio with Guar gum, Xanthan Gum, Ethyl cellulose and Sodium alginate give 
79.32%, 91.52%, 88.35% and 92.19% drug release respectively in 12 hours. In vitro release 
profile of batches F5-F8 shows that Ketorolac Tromethamine in ratio 1:4 with Guar gum, 
Xanthan Gum, Ethyl cellulose and Sodium alginate gives release of 85.21%, 95.52%, 93.50%, 
97.24% respectively in 12 hours. In vitro release profile of batches F9-F12 shows that Ketorolac 
Tromethamine in ratio 1:3 with Guar gum, Xanthan Gum, Ethyl cellulose and Sodium alginate 
gives release of 89.50%, 98.25%, 95.22%, 100.27% respectively in 12 hours. All the batches 
showed no drug release in first two hours in hydrochloric buffer of pH 1.2 and then showed 
higher increase in phosphate buffer of pH 6.0 up to 12 hours. All these batches follow near zero 
order kinetic. 
 
M.S. Shaikh 75 has developed the oral colon targeted drug delivery system for Nimesulide. 
CODESTM tablets were prepared by tabletting Nimesulide and lactulose, followed with film 
coating of Eudragit. The prepared tablets were evaluated on the basis of in vitro dissolution study 
and in vivo disintegration study was performed by gamma scintigraphic evaluation in rats. The 
onset of Nimesulide release was found to dependent on the coating level of Eudragit E, and at 
Eudragit E coating level of 8% (coating weight gain), the onset of in vitro drug release was found 
to be optimum. When the same was subjected on scintigraphic evaluation for in vivo 
disintegration study, there was a reasonable agreement between the in vitro/in vivo data. It is 
concluded that Nimesulide can be targeted to hindgut by a novel approach of CODESTM. 
 
K.Chandramohan et al 76 has investigated, GRAS (Generally regarded as safe) Polysaccharides 
such as Guar gum, Pectin, Dextrin were used as carriers to formulate a colon specific drug 
delivery system for Tinidazole at different ratios of drug: polymer (1:1.5, 1:1.0, and 1:0.5) by 
wet granulation method. The formulated tablets were evaluated. In vitro release studies were 
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performed for their suitability as colon specific drug delivery system. Of the thirteen 
formulations (F1-F13) best formulations were selected which shows restricted drug release in 
small intestine(13.7-36.2%) and which shows more release (56.6-99.9%) in colonic environment 
The selected formulations were enteric coated with Eudragit L-100, to target them to colon. The 
enteric coated tablet (ETF1-ETF6) shows 89.8-96.2% of drug at the end of 10th hour in presence 
of rat caecal medium.  
 
 
S. C. Dhawale et al 77 has given the treatment of colon cancer 5-Fluorouracil is a candidate to be 
delivered orally to the colon; pH - sensitive polymers Eudragit S 100 and L 100 were used to 
prepare microspheres by a simple oil /water emulsification process. Process parameters were 
analyzed in order to optimize the drug loading and release profiles. In further attempts mixtures 
with Eudragit S100 and L100 were prepared to prolong drug release. Scanning electron 
microscopy permitted a structural analysis. Eudragit S100, pure or in mixture, was found to 
retain drug release at pH 4.5 lower than 41% within 6 h. At pH 7.4, nearly immediate release 
(within 30 min) was observed for pure S100, while mixtures enabled to prolong the release 
slightly. Analysis of the morphology led to an inhomogeneous polymer distribution of S100 and 
L 100 throughout the particle core. However, the formulation proved its applicability in-vitro as 
a promising device for pH-dependent colon delivery of 5-fluorouracil. 
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Drug Polymer Profile  
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3.DRUG PROFILE 
  
TRAMADOL HCL31, 32, 33 
 
1. STRUCTURE   : 
                                                                 
 
2. CHEMICAL NAME   :                 (1RS, 2RS)-2-[(Dimethylamino) methyl]-1(3- 
                                                                      Methoxyphenyl) Cyclohexanol Hydrochloride 
 
 
3.  MOLECULAR WEIGHT      :                  299.8 
 
 
4. MOLECULAR FORMULA   :                  C16H26ClNO2 
 
 
5. APPEARENCE                       :            White or almost white, crystalline powder 
 
6. MELTING POINT                  :              178°C (352.4°F) - 181 C 
  
7. FUNCTIONAL CATRGORY:                  Opioid receptor agonist; 
                                                                      Noradrenalin reuptake inhibitor; analgesic 
 
8. SOLUBLITY                           :        Freely soluble in water and in methanol, 
                                                                     Very slightly soluble in acetone 
 
9. STORGAGE                            :        Protected from light. 
 
10. HALF LIFE                             :         Approximately 5–6 hours 
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Indications and Usage for Tramadol HCl Tablets 33 
Tramadol hydrochloride tablets are indicated for the management of moderate to moderately 
severe pain in adults. 
Contraindications 47 
Tramadol hydrochloride should not be administered to patients who have previously 
demonstrated hypersensitivity to tramadol, any other component of this product or opioids. 
Tramadol hydrochloride is contraindicated in any situation where opioids are contraindicated, 
including acute intoxication with any of the following: alcohol, hypnotics, and narcotics, 
centrally acting analgesics, opioids or psychotropic drugs. Tramadol hydrochloride may worsen 
central nervous system and respiratory depression in these patients. 
Table 7: Available dosage forms in market 33: 
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 EUDRAGIT E 100 32,33,34 
 
1.STRUCTURE      : 
                                                          
 
2. MOLECULAR WEIGHT          :        1, 50, 000. 
 
3. APPEARENCE                          :       colorless to yellow tinged granules with a 
                                                                 Characteristic amine-like odour 
 
4. FUNCTIONAL CATRGORY   :       EUDRAGIT E 100 is a cationic copolymer    
                                                                 Based on dimethylaminoethyl                                                                 
                                                                 Methacrylate and neutralmethacrylic esters 
 
5. SOLUBLITY                              :       1 g of EUDRAGIT E 100 dissolves in 7 g 
                                                                 Methanol, ethanol, isopropyl alcohol, Acetone,  
                                                                 Ethyl acetate methylene chloride or 
                                                                 1 N hydrochloric acid to give clear to slightly 
                                                                Cloudy solutions 
 
6. FILM FORMATION                 :       When the Test solution is poured onto a  
                                                                 Glass plate, a clear film forms upon 
                                                               Evaporation of the solvents 
 
7. STORGAGE                              :          Protected from light. 
 
8. LOSS ON DRYING                  :      EUDRAGIT E 100 max. 2.0 % according to  
                                                                  "Dry substance / Residue on evaporation" 
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 EUDRAGIT S 100 32,33,34 
 
1.STRUCTURE       
                                                          
 
2. MOLECULAR WEIGHT         :          1, 35,000. 
 
3. APPEARENCE                          :        White powders with a faint characteristic  
                                                                 Odour 
 
4. FUNCTIONAL CATRGORY   :       EUDRAGIT S 100 is anionic  
                                                                Copolymers based on methacrylic acid and 
                                                                Methyl methacrylate 
  
5. SOLUBLITY                              :        1g EUDRAGIT S 100 dissolves in 7g 
                                                                  Methanol, ethanol, in aqueous Isopropyl  
                                                                 Alcohol and acetone containing approx   
         3% Water as well as in 1 N sodium hydroxide to                     
   give clear to slightly cloudy solutions.          
   Eudragit S100 is practically insoluble in     
   ethyl acetate, methylene Chloride,   
   petroleum ether and water 
 
 
6. FILM FORMATION                   :         When the Test solution is poured onto a  
                                                                   Glass plate, a clear film forms upon 
                                                                  Evaporation of the solvents 
 
7. STORGAGE                                :        Protected from light. 
 
8. LOSS ON DRYING                    :        Max. 5.0 % according to 
                                                                 "Dry substance / Residue on evaporation" 
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HYDROXY PROPYL METHYL CELLULOSE 32, 33, 34 
 
1.STRUCTURE                             :                        
                                                                                                                     
 
                                                             Where R is H, CH3, or CH3CH (OH) CH2 
 
2. CHEMICAL NAME                 :      Cellulose hydroxypropyl methyl ether 
 
 
3. MOLECULAR WEIGHT         :      10 000–1 500 000.  
 
 
4. MOLECULAR FORMULA     :      C16H26ClNO2 
       
 
5. APPEARENCE                       :       odorless and tasteless, white or creamy white 
                                                              Fibrous or granular powder 
 
 
6. MELTING POINT                    :      browns at 190–2008C; chars at 225–2308C. 
                                                              Glass transition temperature is 170–1808C. 
 
7. FUNCTIONAL CATRGORY   :     Coating agent; film-former; rate-controlling  
                                                              Polymer for sustained release; stabilizing  
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                                                              Agent; suspending agent; tablet binder;      
                                                              Viscosity-increasing agent 
 
8. SOLUBLITY                              :    soluble in cold water, forming a viscous Colloidal     
                                                              Solution; practically insoluble in Chloroform, ethanol    
                                                             (95%), and ether, but Soluble in mixtures of ethanol and   
                                                              Dichloromethane, mixtures of methanol and    
                                                              Dichloromethane and mixtures of water and Alcohol  
                                                              Certain grades of hypromellose are Soluble in aqueous   
                                                              Acetone solutions, mixtures of dichloromethane and   
                                                              Propan-2 ol and other organic solvents 
 
9. STORGAGE                               :     Well-closed container, in a cool, dry place. 
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Materials and Methods 
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Table 8: List of excipients used and their sources  
 
 
MATERIALS 
 
 
SOURCES 
Tramadol hydrochloride 
 
NuLife pharmaceuticals pune 
 
Spray dried lactose 
 
Twilight Litaka pharmaceuticals pune 
 
Crosspovidone 
 
Twilight Litaka pharmaceuticals pune 
 
Avicel pH 102 
 
NuLife pharmaceuticals pune 
 
Aerosol 
 
Adinath Chemicals  
Mumbai 
 
Talc 
 
Caltron Clays & Chemicals Private Limited 
Mumbai 
 
Magnesium stearate  
 
Sankalp Organics Private Limited  
Mumbai 
 
Eudragit E 100 
 
Twilight Litaka pharmaceuticals pune 
 
HPMC 2910 
 
Cipla Ltd, Goa (Adinath Chemicals Mumbai) 
 
Eudragit S 100 
 
Cipla Ltd, Goa 
 
Isopropyl alcohol 
 
NuLife pharmaceuticals pune 
 
Polyethylene glycol (PEG) 400 
 
NuLife pharmaceuticals pune 
 
Propylene glycol Shivam Industries, Mumbai  
Mumbai 
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Table 9: List of equipments used and sources: 
 
 
INSTRUMENTS 
 
 
SOURCES 
 
Single pan analytical balance 
 
ANAND Mumbai 
 
Tablet punching machine 
 
CADMACH 16 station single rotary tablet 
punching machine 
Tablet hardness tester 
 
Pfizer tablet hardness tester 
 
Friabilator 
 
VEEGO friabilator 
 
Disintegration apparatus 
 
VEEGO DIGITAL tablet Disintegration apparatus 
 
Magnetic stirrer 
 
KMS- 400 Remi 
 
Coating machine 
 
Bohle coating machine 
Dissolution apparatus 
 
 
ELECTROLAB tablet dissolution tester 
USPXXIV TDT.O8 L 
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5. METHODOLOGY 
 
5.1 Determination of λ max: 
 
10mg/ml solution of Tramadol hydrochloride was taken in specific buffer solution (pH1.2, 
pH7.4, pH6.8) using serial dilution technique and scanned in range 200-400nm using UV 
spectrometer to find out the wavelength of maximum absorbance. 
 
5.2 Construction of standard curve: 
 
100 mg of Tramadol hydrochloride was taken in 100 ml of specific buffer solution (pH1.2, pH 
7.4, and pH 6.8) dissolved properly by shaking and kept on sonicater for 10 min 1 ml of the 
solution was withdrawn and diluted with 100 ml of respective buffer solution and from the stock 
solution 2, 4, 6, 8 and 10ml of solution was transferred into 10 ml volumetric flask and the 
volume was made up to 10 ml to produce 2, 4, 6, 8 and 10 µg/ml solution respectively. 
Absorbance was measured in UV spectrometer at 271nm wavelength. 
 
5.3 Identification test 51:  
 
Weigh about 0.2 gm of test sample add 2ml of water. Acidify with dilute Nitric acid. Add 0.5 ml 
of silver nitrate solution shake and allow to stand; A curdy white precipitate is formed which is 
insoluble in Nitric acid but soluble after being well washed with water in dilute ammonia 
solution from which it is reprecipitated by the addition of dilute Nitric acid. 
 
5.4 Preformulation studies 32, 35, 36: 
Prior to development of a new dosage form with a drug moiety, it is essential that certain 
fundamental physical and chemical properties of the drug candidate and excipients are 
determined. The preformulation parameters like bulk density, tapped density, compressibility 
index Hausner ratios etc. were determined as per USP procedure. The procedures followed for 
various tests are given below: 
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 5.4.1 Bulk Density 36 
           The powder blend under test was screened through sieve no. 18 and the sample equivalent 
to 10 g was accurately weighed and filled in a 25 ml graduated cylinder and the powder was 
leveled and the unsettled volume, V0 was noted. 
The bulk density was calculated in gm / cm3 by the formula,  
Bulk Density (δ0) = M / V0                                                        (1) 
M = Mass of powder taken 
V0 = Apparent unstirred volume 
5.4.2 Tapped Density 36  
The powder blend under test was screened through sieve no.18 and the weight of sample 
equivalent to 10 g was filled in 25 ml graduated cylinder. The mechanical tapping of the cylinder 
was carried out using tapped density tester at a nominal rate of 300 drops per minute for 500 
times initially and the tapped volume V0 was noted. Tapping was proceeding further for an 
additional tapping 750 times and tapped volume, Vb was noted. The tapping was continued until 
the difference between two successive tapped volumes was less than 2%. The tapped density was 
calculated in g / cm3 by the formula, 
Tapped density (δt) = M / Vf    (2) 
M =Weight of sample powder                                                                                                                      
Vf  = Tapped volume 
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5.4.3 Carr’s Index 35 
The bulk density, cohesiveness of the material, surface area, size and shape and the 
moisture content influences the Compressibility index. The compressibility index is determined 
from the bulk volume and tap volume. The basic method used for the determination of 
compressibility index is to measure the bulk volume and the final tapped volume after a fixed 
number of tapping until no change in volume occurs. It is represented in percentage. 
The Carr’s index of the powder was determined by using formula: 
 
Carr’s index (%) = [(TBD - LBD) × 100]/TBD (3) 
Where,  
LBD = weight of the powder/volume of the packing 
TBD = weight of the powder/tapped volume of the packing 
 
Table 10: Standard values for Carr’s index: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carr’s index % Type of flow 
5-15 Excellent 
 
12-18 Good 
 
18-23 Satisfactory 
 
23-35 Poor 
 
35-38 Very poor 
 
>40 
 
Extremely poor 
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5.4.4 Hausner ratio 44: 
Hausner’s ratio is the ratio of the initial volume of the powder mass to the final volume of 
the powder mass obtained after the specified number of tapping. 
Hausner ratio is calculated from the formula, 
 Hausner ratio= (δt / δ0) (4) 
        δt = Tapped density 
                                  δ0`= Bulk density 
 Table 11: Scale of Flowability based on Hausner’s Ratio 
 
 
 
 
 
 
 
 
5.4.5 Angle of Repose 36 
         Angle of repose is defined as maximum angle formed between surface of pile of powder 
and horizontal plane. It is determined by the funnel method. 10g of the powder was accurately 
weighed and taken in a funnel closed at the bottom with a cotton plug. Height of the funnel was 
adjusted such that the tip of the funnel just touches the apex of the heap of powder. The powder 
was allowed to flow through funnel freely onto the surface. The diameter of the powder cone 
was measured and angle of repose was calculated using the following equation no 5.  
 
 
Tan θ = h/r                                                                                                 (5) 
Therefore, θ = Tan-1h/r 
Where, θ = angle of repose, h = height of the cone and r = radius of the cone base 
HAUSNER’S RATIO FLOW CHARACTER 
1-1.11 Excellent  
1.12-1.18 Good  
1.19-1.25 Fair  
1.26-1.34 Passable  
1.35-1.45 Poor  
1.46-1.59 Very poor  
>1.60 Very, very poor 
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Table 12: Standard values for Angle of repose: 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.6 Compatibility Studies: 
IR spectra matching approach was used for detection of any possible chemical interaction 
between drug and polymer. A pure drug, uncoated tablet and coated tablets were separately 
mixed with three suitable quantity of potassium bromide. About 100mg of mixture was 
compressed to form a transparent pellet using a hydraulic press at 6tons pressure .It was scanned 
from 4000 to 400 cm-1 in FTIR spectrometer. The IR spectrum of the physical mixture was 
compared with those of pure drug and polymers and matching was done to detect any appearance 
or disappearance of peaks. The IR spectrums of the tablets in the range of 4000 cm-1 to 400 cm-
1 were taken by preparing dispersion in dry potassium bromide under the same operational 
conditions mentioned above. 
 
 
 
 
 
 
 
 
Angle of repose in degrees Type of flow 
 
<25 Excellent 
 
25-30 Good 
 
30-40 Satisfactory 
 
>40 Poor 
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5.5 Formulation of tablets for colon targeting: 
The tablets for colon targeting was developed by preparing a core tablet containing 100mg of 
Tramadol HCl, which was the coated with pH sensitive polymers such as Eudragit S100, E100 
and HPMC in three stages. 
5.5.1 Preparation of core tablets of Tramadol HCl: 
Core tablets of Tramadol HCl were prepared by direct compression method, as per the formula 
given in Table no 13. 
Table 13: Formula used for core tablet: 
 
The ingredients required were weighed accurately and mixed thoroughly using a powder blender 
and sieved through sieve no.80. The powder blend was then lubricated with the addition of talc 
and magnesium stearate. The lubricated blend was then compressed into tablets by using a 16 
station rotary tablet punching machine (Cadmach, Ahmedabad). The compression parameters 
used are given in Table no 14. 
 
 
 
 
INGREDIENTS  QUANTITY TAKEN (mg)  
Tramadol hydrochloride  100  
Spray dried lactose  208  
Crosspovidone  22  
Microcrystalline cellulose  150  
Aerosil  20  
Talc  25  
Magnesium stearate  25  
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Table 14: Compression parameters: 
NAME OF MACHINE CADMACH 16 station tablet punching 
machine 
NUMBER OF STATION 16 
ROATION PER MINUTE 4-5 
COMPRESSION PRESSURE 40-65 kilo Newton 
PUNCH SIZE 5×18mm 
TOOLING B Tooling 
 
5.6 EVALUATION OF CORE TABLETS: 
5.6.1 Thickness testing 49 
 
The thickness of the matrix tablets was determined by using vernier calipers, and the results are 
expressed as mean values of 10 determinations. 
 
5.6.2 Tablet Hardness 49 
The hardness of the tablet was measured by pfizer hardness tester. The tablets were held 
vertically in between the jaws, which were pressed with hand until the tablet broken. The reading 
was noted from needle which was expressed in kg. A total of three tables were tested and the 
mean values were reported. 
 
5.6.3 Weight Variation 36 
Weight variation test for the core tablets was performed as per the IP procedure. Twenty tablets 
were weighed individually and the average weight was determined. The individual weight of all 
the twenty tablets was noted. The percentage deviation of the individual weights from the 
average weight was then calculated. Deviation should not exceed the values given in table no 15 
Average weight of 
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Table 15: Percentage deviation allowed in weight variation: 
AVERAGE WEIGHT OF 
TABLET 
PERCENTAGE DEVIATION 
(±) 
80 mg or less 10 
 
More than 80 mg but less than 
250mg 
7.5 
 
250 mg or more 5 
 
 
5.6.4 Friability 36 
         
           Friability was performed to evaluate the ability of tablet to withstand abrasion. VEEGO 
friabilator was used for testing the friability. Twenty tablets were weighed accurately and placed 
in the tumbling apparatus that revolves at 25 rpm. After 4 min., the tablets were weighed and the 
percentage loss in tablet weight was determined. 
 
 
             Initial wt. of tablets - Final wt. of tablets 
% loss = ------------------------------------------- x 100 (6) 
                     Initial wt. of tablets 
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5.6.5 Assay: 
 
Standard preparation: 
Weigh accurately 0.11 gm of Tramadol hydrochloride (working formula) in 10ml of volumetric 
flask which is previously dried with Methanol. Dilute to the mark with methanol to get final 
concentration i.e. 1.1mg/ml 
 
Test preparation: 
Weigh 20 tablets and powder them.  Take powdered tablet equivalent to 0.011gm i.e. about 
0.16gm in 100ml of beaker which is previously dried. Add 50ml of chloroform in it. Keep it on 
ultrasonic bath for 15-20 min with slight heating then filter the chloroform in another dry beaker 
and evaporate chloroform to dryness. After evaporation make dilution with methanol to 10ml by 
rinsing the beaker. The absorbance of the diluted solution was then measured at 271nm using 
methanol as the blank solution. The assay value is calculated by using the formula: 
 
Assay =     ܂܍ܛܜ ܚ܍܉܌ܑܖ܏     ܁ܜ܉ܖ܌܉ܚ܌ ܚ܍܉܌ܑܖ܏     ×    ܅ܑ܍܏ܐܜ ܗ܎ ܛܜ܉ܖ܌܉ܚ܌܅܍ܑ܏ܐܜ ܗ܎ ܜ܍ܛܜ    × 100 (7) 
 
 
5.7 Preparation of coated tablets: 
The core tablets prepared were then coated with two different pH sensitive polymers, Eudragit 
E100 and S100 and by using HPMC as the barrier coating material. The sequence of coating is as 
follows; 
 
1)  10% Eudragit E100 50 coated immediately over the core tablet  
      2)  10% HPMC was then coated over the E100 coating as a barrier coat. 
      3)  6% Eudragit S 100 35 was coated as the outer most coating. 
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• EUDRAGIT E100:- Cationic polymer carries amino groups insoluble in neutral medium 
of saliva but dissolves in acid medium of gastric fluid. The polymer becomes permeable 
at a pH of more than 5.5 
• EUDRAGIT S100:-Anionic polymer carry carboxyl groups insoluble in acid medium i.e. 
resistant to gastric fluid and dissolves in alkaline medium of intestine 
• HPMC:-This layer acts as barrier layer and prevents the possible interaction between 
EudragitE100 & Eudragit S100.  
 
Table 16: Coating composition for the three polymers: 
POLYMERS 
 
SOLVENT USED PLASTICIZERS USED 
IN % 
 
 
EUDRAGIT       E-100 
 
ISOPROPYL ALCOHOL  
 
--------- 
 
HPMC  
 
WATER PROPYLENE GLYCOL15% 
+ 
TALC 10% 
 
EUDRAGIT      S-100  
 
ISOPROPYL ALCOHOL PEG-400 
2% 
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Table 17: Coating polymer ratio: 
 
 
5.8 Coating method: 
 
Coating was done by three successive layers in coating pan by spray pan coating method, 
 
5.8.1 Coating of Eudragit E100 solution: 
 
100 ml of Isopropyl alcohol was taken in clean and dried beaker and kept on magnetic stirrer. 
Accurately weighed amount (10gm) of EUDRAGIT E 100 was slowly added in beaker and 
beaker was closed with a polyethylene cover to avoid evaporation during stirring. The coating 
solution was kept for 30 min and this (10% Eudragit E100 solution) was sprayed on tablet by 
using 12" coating pan with following parameters given below in table no 18. 
 
 
 
 
 
 
 
POLYMER 
 
 
%WEIGHT GAIN ( COATING LEVEL ) 
 
F-1 
 
F-2 
 
F-3 
 
F-4 
 
F-5 
 
F-6 
 
F-7 
 
F-8 
 
F-9 
 
EUDRAGIT       S-100 
 
3 
 
3 
 
3 
 
6 
 
6 
 
6 
 
9 
 
9 
 
9 
 
HPMC  
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
5 
 
EUDRAGIT      E-100  
 
3 
 
6 
 
9 
 
3 
 
6 
 
9 
 
3 
 
6 
 
9 
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5.8.2 Coating of HPMC barrier layer: 
Second barrier layer coat was given to avoid any possible interaction between Eudragit E100 and 
Eudragit S100 since they are oppositely charged polymers and they may have attraction towards 
each other. The coating solution was prepared by taking 10 gm of HPMC2910 and added slowly 
in 100ml (10% of HPMC2910 solution) of water and volume was adjusted after adding 
plasticizers, propylene glycol 15% and Talc 10%. Then this coating polymer was stirred for 5-7 
min, filtered and then sprayed on the same batch of tablet previously coated with Eudragit E100. 
 
5.8.3 Coating of Eudragit S100: 
Third coating layer was prepared by taking 6gm of Eudragit S100 in a beaker (which is dried) 
containing 100 ml of Isopropyl alcohol with 2% of propylene glycol as a plasticizer and stirred in 
magnetic stirrer for 30 min and beaker was closed with a polyethylene cover to avoid 
evaporation during stirring. This (10% Eudragit S100 solution) was sprayed on tablet by using 
12" coating pan with following parameters given below in table no18. 
 
Table 18: Coating parameters: 
AIR PRESSURE (kg/cm2) 1.5-2.5 
 
PAN SPEED (RPM) 4-5 
BED TEMPERATURE 35-400 C 
 
NUMBER OF BAFFELS 2 
NUMBER OF SPRAYING GUN 1 
GUN DISTANCE  
(cm) 
FOR HPMC COAT 
(aqueous) 
FOR EUDRAGIT 
COAT (non aqueous) 
20-25 15-18 
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5.9 Evaluation of coated tablets: 
The coated tablets were subjected to various evaluation tests similar to that of the uncoated 
tablets, such as thickness, hardness, friability, weight variation, assay etc. Apart from the above 
studies, the tablets were also subjected to in vitro drug dissolution studies using different 
mediums simulating the GIT environment. 
 
5.9.1 In vitro drug release studies 37 
          In vitro drug release studies were carried out using USP XXIV dissolution test apparatus 
Type II, paddle apparatus (50 rpm, 37+ 0.50 C). In vitro release study for enteric coated tablets 
was carried out by keeping the tablets for 2 h in pH1.2 (900 ml) acid buffer solution, simulated 
gastric fluid (SGF). The dissolution medium was then replaced with pH 7.4 phosphate buffer 
solution (900 ml), simulated intestinal fluid (SIF), and tested for 3 h, which was later replaced by 
pH 6.8 phosphate buffer solution (900 ml), simulated colonic fluid (SCF), and tested for release 
for 19 h. The drug release at different time intervals was analyzed by UV double beam 
spectrophotometer (Electrolab TDT-08 L) at 271 nm  
 
5.9.2 Release kinetic analysis 
To study the release kinetics, data obtained from in- vitro drug release studies were 
plotted in various kinetic models: zero order (Equation 8) as cumulative amount of drug released 
vs. time, first order 78 (Equation 9) as log cumulative percentage of drug remaining vs. time, and 
Higuchi’s model 79 (Equation 10) as cumulative percentage of drug   released vs. square root of 
time. 
C = K0 t     (8) 
Where 
K0 : is the zero-order rate constant expressed in units of concentration/time  
t: is the time in hours.  
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A graph of concentration vs. time would yield a straight line with a slope equal to K0 and 
intercept the origin of the axis. 
LogC = LogCo−kt/2:303      (9) 
Where 
  C0: is the initial concentration of drug,  
  K: is the first order constant, and t is the time. 
Q = Kt1/2          (10) 
Where 
  K: is the constant reflecting the design variables of the system  
   t: is the time in hours.  
 
Hence, drug release rate is proportional to the reciprocal of the square root of time. 
 
 To evaluate the drug release with changes in the surface area and the diameter of the 
particles/tablets, the data were also plotted using the Hixson-Crowell cube root law 80: 
0 t3 Q -3 Q =kHC-t        (11) 
 
Where Qt is the amount of drug released in time t,  
Q0 is the initial amount of the drug in the tablet,  
And KHC is the rate constant for the Hixson-Crowell rate equation, as the cube root of the 
percentage of drug remaining in the matrix vs. time. 
 
Mechanism of Drug Release 81, 82 
        Higuchi’s plot has indicated that   diffusion   might be one of the   prominent mechanisms 
influencing the drug release. To evaluate the mechanism of drug release from Tramadol tablets, 
data of drug release were plotted in Korsmeyer et al’s Equation 12 as log cumulative percentage 
of drug released vs. log time, and the exponent n was calculated through the slope of the straight 
line. 
                                         Mt-M∞ = Ktn                            (12) 
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 Where 
        Mt/M∞ is the fractional solute release,   
         t is the release time, 
        K is a kinetic constant characteristic of the drug/ polymer system, and n is an exponent that 
characterizes the mechanism of release of tracers.  
 
5.9.3 Stability studies: 
Stability study was done to check out the quality of drug substance or product varies with time 
under the influence of a variety of environmental factors such as temperature, humidity, and 
light; to establish a retest period for the drug substance or a shelf life for the drug product and 
recommended storage condition.  
Here the tablets were loaded at accelerated condition at 400C±2 0 and 75% RH in a stability 
chamber. Sample were withdrawn after 30 and 60 days and analyzed suitably for the drug 
content and dissolution characteristics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
Results and Discussion 
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6. RESULTS AND DISCUSSION 
 
6.1 Determination of λ max:  
 
                     The wavelength showing maximum absorbance (λ max) for Tramadol 
hydrochloride was determined by scanning the standard stock solution of the drug using UV 
visible spectrophotometer. The λ max was found to be 271nm for Tramadol HCl which is in 
accordance with the data available in literature.83 
 
6.2 Calibration curve:  
 
                  A standard calibration curve of Tramadol HCl was constructed in three different 
mediums such as pH1.2, 7.4, and 6.8 respectively by measuring the absorbance of Tramadol HCl 
solution of concentrations ranging from 2-10ug/ml. The absorbance data and calibration curve is 
shown in tables 19-21 and figures 9-11. The calibration curve obtained from all the three 
different medium showed regression value of about 0.994-0.998. The higher regression value 
obtained indicates good linearity between concentration and the measured absorbance for 
Tramadol HCl 
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Table 19: Calibration curve data of Tramadol hydrochloride in buffer pH 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
Fig 9: Standard graph for pH 1.2 acid buffer 
 
 
 
 
 
 
y = 0.009x + 0.001
R² = 0.994
0
0.02
0.04
0.06
0.08
0.1
0.12
0 5 10 15
pH1.2
abs
Linear (abs)
Concentration 
(µg) 
Absorbance 
(271nm) 
0 0 
2 0.021 
4 0.032 
6 0.045 
8 0.067 
10 0.082 
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Table 20: Calibration curve data of Tramadol hydrochloride in buffer pH 7.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
Fig 10: Standard graph for pH 7.4 phosphate buffer 
  
 
 
 
 
 
 
y = 0.009x + 0.000
R² = 0.996
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8 0.064 
10 0.087 
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Table 21: Calibration curve data of Tramadol hydrochloride in buffer pH 6.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
 
 
Fig 11: Standard graph for pH 6.8 phosphate buffer 
 
 
 
 
 
 
 
 
y = 0.006x + 0.000
R² = 0.998
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(271nm) 
0 0 
2 0.013 
4 0.026 
6 0.034 
8 0.062 
10 0.065 
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6.3 Preformulation study:  
Preformulation studies for the prepared powder blend were performed in order to evaluate the 
physicochemical properties and to analyze whether the prepared blend will be suitable for 
preparation of tablets using direct compression method. Various parameters evaluated are Angle 
of repose, Bulk density, Tapped density, Compressibility index and Hausner’s ratio. The results 
obtained from the above studies are shown in table 22. The powder blend had an angle of repose 
of about 230 suggesting that the powder is having good flowability. The Carr’s index was found 
to be 17.2% and Hausners ratio was found to be 0.82 these values indicates that the prepared 
powder blend have sufficient flowability and compressibility and hence can be processed 
comfortably by direct compression method.  
 
Table no22: Result for preformulation studies: 
 
 
 
 
ANGLE OF 
REPOSE 
(degree) 
 
 
 
 
 
 
BULK 
DENSITY 
(gm/cm3) 
 
 
 
 
 
 
TAPPED 
DENSITY 
(gm/cm3) 
 
 
 
 
 
 
CARR’S 
INDEX 
(%) 
 
 
 
 
 
 
HAUSNERS 
RATIO 
 
 
 
 
 
230 
 
 
 
 
0.66 
 
 
 
 
0.54 
 
 
 
 
17.2 
 
 
 
 
0.82 
 
 
 
 
6.4 Compression of tablets: 
Core tablets of Tramadol HCl were compressed by using 16 station rotary tablet punching 
machine (CADMACH Ahmadabad) to a target weight of 550mg. There were no significant 
processing problems during the compression process and all the prepared tablets were found to 
be uniform in shape and size. 
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6.5 Coating of tablet: 
 
The core tablets prepared were then coated with three different polymers such as Eudragit E100, 
HPMC and Eudragit S 100. The immediate coat on the core tablet was done with Eudragit E100. 
Initially Acetone was used as solvent for Eudragit E100 and was used for coating of core tablet. 
During the coating process the polymer solution with acetone as solvent could not produce a 
proper coat on the tablets. Acetone being highly volatile and the higher temperature inside the 
coating pan lead to rapid evaporation of solvent before it reaches the tablet bed and hence the 
tablet got rough appearance on the surface and the coating was not efficient. In order to avoid 
this problem the solvent was changed to Isopropyl Alcohol (IPA).  The IPA solution produced a 
uniform and smooth coating over the core tablets. Coating was continued till there was a net 
weight increase of about 3% of the average weight for first batch, 6% for the second and 9% for 
the third formulation. The tablet coated with Eudragit E100 was subjected to barrier coating 
using HPMC as the polymer. A barrier coating was done until a net weight increase of about 5% 
was achieved for all the formulations. 
 
               A third layer coating was done to the barrier coated tablet using Eudragit S100 to make 
them resistant to gastric fluid. IPA was used as solvent for Eudragit S100 and polyethylene 
glycol and talc was added as a plasticizer. The tablets were coated in three batches to a target 
weight increase of about 3%, 6%, and 9% respectively. The coated tablets were found to be 
smooth without any defects and the coating was uniform throughout the batches. 
 
6.6 Evaluation of tablets: 
 
         The core tablets and coated tablets were evaluated for various evaluation tests such as 
hardness, thickness, friability, weight variation, drug content etc. The results obtained from the 
above studies were given in table 23 and 24. The hardness of core tablet ranged from 6.16 to 
6.66kg/cm3. These values indicate that the prepared tablet have sufficient mechanical strength to 
withstand any sort of pressure during handling and storage. The hardness after coating was found 
to be slightly increased with values ranging from 6.63 to 7.3. This increase in hardness of the 
tablet after coating suggests that the polymers have given more strength to the tablet. 
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        The friability test done on the core tablet gave a percentage weight loss of about 0.059 to 
0.426 which is well within the prescribed limit of 1% as per the IP. Interestingly friability values 
for the coated tablets were almost 0% for all the formulations except F-1 which shows value of 
0.0138% weight loss. These values pronounced that the coating of the polymer was complete and 
uniform throughout all the formulation and they have given tremendous strength to these tablets 
such that they can withstand any sort of mechanical and physical shocks either during handling 
and storage or during transportation. 
 
Table no 23: Results for evaluation of tablet before and after coating: 
FORMULA 
CODE 
HARDNESS 
BEFORE 
COATING 
Kg/cm2 
HARDNESS 
AFTER 
COATING 
Kg/cm2 
FRIABILITY 
BEFORE 
COATING 
(%) 
FRIABILITY 
AFTER 
COATING 
(%) 
F-1 6.433 
±0.0577 
 
6.63 
±0.057 
 
0.1815 
 
0.0138 
 
F- 2 6.5 
±0.1732 
 
6.63 
±0.115 
 
0.1054 
 
0 
F-3 6.66 
±0.115 
 
6.87 
±0.057 
 
0.3555 
 
0 
F-4 6.63 
±0.057 
 
6.733 
±0.115 
 
0.2289 
 
0 
F-5 6.66 
±0.208 
 
6.86 
±0.208 
 
0.1062 
 
 
0 
F-6 6.533 
±0.635 
 
6.60 
±0.1 
 
0.0761 
 
0 
F-7 6.34 
±0.152 
 
6.59 
±0.1 
 
0.0599 
 
0 
F-8 6.16 
±0.404 
 
6.67 
±0.057 
 
0.4269 
 
0 
F-9 6.34 
±0.46 
 
7.0 
±0.2 
 
0.0760 
 
0 
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Drug content in the prepared formulations were analyzed by performing the assay as per the 
procedure given in methodology section. The assay value ranged from 98.05 to 101.73% for the 
core tablet and the values did not show any significant changes for the coated tablets. These 
results clearly demonstrate that the coating procedure of the polymers used for coating does not 
have any significant impact on the drug content and also there was no interaction between the 
drug, polymer and the solvent used. 
 
Table no 24: Results for evaluation of tablet before and after coating: 
 
 
 
FORMULA 
CODE 
 
 
 
THICKNESS(mm) 
 
DRUG 
CONTENT (%) 
BEFORE 
COATING 
 
DRUG 
CONTENT (%) 
AFTER 
COATING 
F-1 5.133 
±0.1154 
 
99.61 
 
 
99.59 
F-2 5.133 
±0.058 
 
98.05 
 
98.00 
F-3 5.166 
±0.1527 
 
99.21 
 
99.21 
F-4 5.233 
±0.0578 
 
98.95 
 
98.93 
F-5 5.233 
±0.1527 
 
99.85 
 
99.85 
F-6 5.066 
±0.1154 
 
98.67 
 
98.67 
F-7 5.233 
±0.1527 
100.59 
 
100.28 
 
 
F-8 5.233 
±0.1527 
 
101.73 
 
101.67 
F-9 5.233 
±0.0577 
 
99.98 
 
100.04 
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Weight variation test for the core tablet and coated tablet after each stage of coating was 
performed as per pharmacopoeial procedure. Since the coating target was fixed based on net 
increase in average weight of the tablet it was necessary to check the weight variation after each 
stage of coating with the three different polymers. Average weight obtained for the core tablet 
and for tablet after each coating is within the prescribed limits of ±5% and hence all the 
formulations passes the weight variation test. The average weight increase after each stage of 
coating can be clearly seen in the table 25 this increase in weight clearly indicates that coating 
has been done efficiently and the required net increase in tablet weight was achieved. 
Table no 25: Results for weight gain after different layers of coating in all batches: 
FORMULATION 
CODE 
WEIGHT OF 
TABLET 
BEFORE 
COATING 
(mg) 
WEIGHT OF 
TABLET 
AFTER FIRST 
COATING 
(mg) 
WEIGHT OF 
TABLET 
AFTER 
SECONDCOATING 
(mg) 
WEIGHT OF 
TABLET 
AFTER THIRD 
COATING 
(mg) 
F-1 553 
±0.0087  
 
564 
±.00309  
 
588 
±0.0016  
 
610 
±0.0017  
 
F-2 550 
±0.0106  
 
562 
±0.0028  
 
592 
±0.0029  
 
626 
±0.0063  
 
F-3 549 
±0.0131  
 
562 
±0.0021  
 
591 
±0.0045  
 
647 
±0.0011  
 
F-4 544 
±0.0082  
 
579 
±0.0028  
 
611 
±0.0013  
 
629 
±0.0846  
 
F-5 554 
±0.0100  
 
580 
±0.0014  
 
611 
±0.0011  
 
646 
±0.0027  
 
             F-6 549 
±0.0121  
 
581 
±0.0015  
 
610 
±0.0016  
 
663 
±0.0025  
 
F-7 549 
±0.0121  
 
594 
±0.0036  
 
627 
±0.0034  
 
646 
±0.0031  
 
F-8 547 
±0.0155  
 
596 
±0.0037  
 
626 
±0.0056  
 
665 
±0.0021  
 
F-9 553 
±0.0175  
 
593 
±0.0038  
 
628 
±0.0039  
 
683 
±0.0038  
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6.7 Compatibility studies: 
                           IR spectra matching approach was used for detection of any possible chemical 
interaction between drug and polymer. Pure drug, uncoated tablet and coated tablets were taken 
in powder form and separately mixed with three suitable quantities of potassium bromide. About 
100mg of mixture was compressed to form a transparent pellet using a hydraulic press at 6tons 
pressure. It was scanned from 4000 to 400 cm-1 in FTIR spectrometer. The IR spectrum of the 
physical mixture was compared with those of pure drug and polymers and matching was done to 
detect any appearance or disappearance of peaks. The IR spectrums of the tablets in the range of 
4000 cm-1 to 400 cm-1 were taken by preparing dispersion in dry potassium bromide under the 
same operational conditions mentioned above. The spectrum obtained is shown in Figs.12, 13 
and 14 
 
Fig 12: IR Spectra of Tramadol HCl 
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Fig 13: IR Spectra of Uncoated tablet 
 
 
 
 
 
 
 
90 
 
 
 
Fig 14: IR Spectra of Coated tablet 
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Table 26: Characteristic peaks of Tramadol HCl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The data given in a table 26 shows the characteristic peaks detected in the IR spectrum of pure 
Tramadol HCl tablets. The spectra of the coated and uncoated tablets were compared with the 
spectra of pure drug and the presence or absence of the characteristic peaks was observed. It was 
found that the spectra of the tablets showed all the characteristic peaks observed in the pure 
sample suggesting that the drug is intact and no compatibility problems were found between the 
drug, polymer and other excipents. 
 
 
 
 
 
 
 
SERIAL 
NUMBER 
WAVENUMBER SPECIFICATION 
 
1 1048cm-1 C-O-C stretch of Aryl alkyl 
Ether- Symmetric 
2 1242cm-1 C-O-C stretch of Aryl alkyl 
Ether- Asymmetric 
3 1384cm-1 C-N Stretching 
 
4 2929cm-1 
2860 cm-1 
CH3-CH Stretching 
5 3372cm-1 OH Stretching Vibration 
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6.8 In vitro drug release studies: 
An ideal colon targeted drug delivery system should release the drug only in colon area to get 
maximum benefits with regard to drug absorption and oral bioavailability. Hence to analyze the 
drug release pattern of the prepared tablets, in vitro drug release studies were performed at three 
stages. 
 
In first stage 900ml simulated gastric fluid of pH 1.2 was used as dissolution medium for two 
hours for mimicking the transit time in stomach. 
 
In the second stage dissolution was continued for further three hours mimicking small intestinal 
transit time in 900ml simulated intestinal fluid of pH7.4. 
 
The studies were continued for further 19 hours using 900ml simulated colonic fluid pH 6.8 
mimicking large intestinal transit time. Thus dissolution studies were performed for a total of 24 
hours and the result obtained were given in table 27. 
 
The drug release data in pH 1.2 buffer showed almost nil release except in F-1 which showed a 
negligible amount of about 3% in the first two hours. The obtained data from second stage of the 
released studies in pH 7.4 gave cumulative percentage release ranging from 6.22 to 51.07% after 
3 hours. The formulation F-1, F-4 and F-7 which contains 3%, 6% and 9% respectively of 
Eudragit S100 and 3% of Eudragit E100 gave a release of 51.07%, 39.1% and 13% respectively 
after 5 hours in simulated intestinal fluid. From the values we can observe that as the level of 
Eudragit S100 was increased the percentage release of drug was found to be decreased, Similar 
pattern of release was also found in F-2, F-5 and F-8 formulation coated which contains constant 
6% of Eudragit E100 with 3%, 6% and 9% Eudragit S100 gave values of 47.58, 26.79 and 7.13% 
respectively. Formulation F-3, F-6 and F-9 having 9% Eudragit E100 coating solution with 3, 6 
and 9% Eudragit S100 coating gave a cumulative release of 39%, 21.10% and 6.22%  at 5h in 
simulated intestinal fluid and is depicted in fig 15,16 and17. 
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Table no 27: Results for in vitro release studies (% cumulative release):  
 
Time F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 
0.5 0 0 0 0 0 0 0 0 0 
1 1.11 0 0 0 0 0 0 0 0 
1.5 2.06 0 0 0 0 0 0 0 0 
2 3 0 0 0 0 0 0 0 0 
          
2.5 3.22 1.71 1.01 0.99 0.50 0.50 0.23 0.00 0.00 
3 9.50 7.83 5.59 3.24 2.30 2.01 2.00 2.98 1,88 
3.5 16.07 13.33 11.98 7.20 5.11 4.99 3.77 3.73 2.07 
4 25.73 24.00 19.11 16.31 14.16 12.42 7.15 5.87 3.42 
4.5 39.98 31.31 24.43 27.43 21.27 16.55 10.39 8.91 5.01 
5 51.07 47.58 39.10 39.10 26.79 21.10 13.00 7.13 6.22 
          
5.5 60.01 52.72 40.09 41.01 27.00 22.22 15.22 12.10 7.00 
6 68.11 55.60 48.72 44.70 31.98 24.89 18.19 16.01 9.10 
6.5 73.03 59.58 51.91 47.70 37.72 27.01 23.74 21.11 12.00 
7 75.51 63.25 57.63 51.03 44.00 33.73 27.15 24.00 16.03 
7.5 81.22 71.44 62.99 56.65 50.60 39.00 33.17 26.72 19.23 
8 89.13 83.36 75.77 59.99 66.60 45.12 38.01 30.33 27.72 
8.5 95.43 89.32 79.98 65.51 68.36 51.21 45.73 35.44 33.98 
9 97.71 93.16 84.21 73.57 70.04 55.75 52.41 41.99 40.78 
9.5 98.00 95.10 89.95 77.42 72.33 58.27 57.42 45.09 50.76 
10 98.09 95.11 90.41 81.21 73.59 64.88 62.15 47.16 55.76 
11   93.33 83.32 75,07 67.22 64.79 51.40 59.98 
12   96.01 88.78 77.04 71.51 68.01 55.41 59.43 
13   97.39 90.01 81.89 75.24 71.71 61.73 61.64 
14   98.02 92.23 85.05 81.00 78.32 69.37 64.07 
16   98.09 95.14 90.51 85.44 80.62 74.33 68.38 
18    98.50 98.07 88.73 97.16 89.77 73.33 
20    98.95 98.20 97.16 98.02 92.89 76.77 
24        99.04 83.98 
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On careful observation of above data it can be understood that the drug release tend to decrease 
with increase in the polymer content of both E100 and S100.  
 
The third stage of dissolution study was performed for a further period of 19 hrs using simulated 
colonic fluid pH 6.8. The dissolution profile showing the effect of Eudragit E100 is depicted in 
fig 18, 19 and 20. It was interesting to note that the pattern of release follows a similar way in 
simulated colonic fluid also. The drug release was almost complete with F-1 and F-2 within 10 
hrs of the study where as the formulation F-3 shows a complete release at 16 hrs followed by F-
4, F-5, F-6 and F-7 which gave complete release of the drug within 20 hrs of the study. 
Formulation F-8 with 9% Eudragit S100and 6% E100 gave a near 100% release after 24hrs 
which seems to be the best among 9 formulations. Formulation F-9 gave a percentage cumulative 
release of about 83% at the end of 24hrs which suggest that the formulation could not release its 
entire content within the desired time limit of 24hrs. 
 
These data suggest that the formulation F-8 can be chosen as the best among 9 formulations 
prepared as it produced maximum release in colonic fluids (>90%) and also gave complete 
release in 24hrs. 
 
 
Effect of Eudragit S100 on the drug release: 
 
The dissolution profile of formulations (F1, F4 & F7) containing 3, 6 & 9% coating level of 
S100 and 3% of E100 is shown in Fig.15. Eudragit S100 is an enteric polymer which will not 
dissolve in simulated gastric fluid and hence the prepared formulations did not show any drug 
release in the first two hours when the dissolution was performed in pH 1.2 buffer. In the next 
stage, when the studies were continued in pH 7.4 buffer, the polymer coating of S100 gets 
dissolved and exposes the barrier coating layer of HPMC. HPMC being hydrophilic in nature 
tends to swell and disintegrate and thus exposes the Eudragit E100 layer. Although Eudragit 
S100 is completely soluble in pH 7.4, the formulations with increasing S100 content exhibited a 
decrease in the amount of drug released during the second stage of the releases studies. This can 
be explained by the fact that formulations F-1, F-4 and F-7 containing 3% Eudragit E100 and 3, 
6 & 9 % Eudragit S100 gave a cumulative release of 51.07, 39 & 13% respectively. These data 
95 
 
suggests that when the coating level of Eudragit S100 was increased, the time taken for the 
complete dissolution of the coating also gets increased and hence the cumulative release of the 
drug was reduced. The dissolution profiles of formulations with 6% & 9% Eudragit E100 were 
shown in fig.16&17. These profiles also follow a similar pattern of release producing a decrease 
in the percentage release of drug with increase in the polymer content. 
 
. 
 
Fig 15: Dissolution Profile of 3, 6, and 9% Eudragit S100 and 3% Eudragit E100  
 
. 
 
Fig 16: Dissolution Profile of 3, 6, and 9% Eudragit S100 and 6% Eudragit E100 
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Fig 17: Dissolution Profile of 3, 6, and 9% Eudragit S100 and 9% Eudragit E100 
  
 
 
Effect of Eudragit E100 on drug release 
 
Eudragit E100 is an acid soluble polymer, which is insoluble at pH 7.4 and 6.8. But it becomes 
more permeable at a pH of above 5.5. In the second stage of the dissolution studies where pH 7.4 
buffer was used, the layer of S100 coating and barrier layer of HPMC gets dissolved completely 
exposing the E100 layer above the core tablet. Since the polymer is permeable above pH 5.5, it 
allows for the drug permeation and hence drug is released slowly from the core tablet. The 
dissolution profiles of formulations with constant amount of S100 coating and varying amount of 
E100 coating were shown in Fig.18, 19 & 20. The percentage release of the drug after 3 hours in 
pH 7.4 buffer gave values ranging from 6.22% for F-9 to 51.07% for F-1 formulations.  
 
Careful observation of the dissolution data reveals the fact that the drug release was inversely 
proportional to the polymer content in the coating layer. This can be explained with the 
following example. The formulations with 3% S100 coating and 3, 6 & 9% E100 coatings gave a 
cumulative release of 51.07, 47.58 & 39.10% after 5h of the study. The same formulations 
released about 98.09%, and 95.11% in 10h, and 98.09% in 16h respectively in colonic pH. The 
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formulation with 3% E100 coating released the entire contents within 10h, whereas formulations 
with 6 & 9% coating of E100 produced a prolonged release for 16h. Similarly, formulations F4, 
F5 & F6 with a constant 6% S100 coating and 3, 6 & 9 % coating of E100 polymer gave a 
cumulative release of about 98.95%, 98.2% and 97.16% respectively, in 20h. 
 
From the above data, it is evident that the polymer content plays a significant role in altering the 
drug release characteristics of the tablets. 
 
On basis of the in vitro release characteristics of the prepared formulations, formulations F8 & 
F9 containing 9% Eudragit S100 coating along with 6 & 9% Eudragit E100 coating respectively 
were selected as the best among the nine formulations. These two formulations gave a release of 
more than 90% in the colonic pH and a meager 7.13 & 6.22 % in the intestinal pH making them 
most suitable for colon targeting. Among these two, F8 with 9% S100 coating and 6% E100 
coating was selected as the best one, based on the reason that it produced maximum release in 
the colonic pH and also gave almost 100% release in 24h whereas formulation F9 could produce 
only 83.98% release at the end of 24h. 
 
. 
 
Fig 18: Dissolution Profile of Formulation F-1, F-2and F-3 
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Fig 19: Dissolution Profile of Formulation F-4, F-5and F-6 
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Fig 20: Dissolution Profile of Formulation F-7, F-8and F-9 
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6.9 Kinetic analysis 
The in vitro drug release data were subjected to kinetic analysis by plotting various kinetic 
equations like zero order, first order, Higuchi, and Hixon crowells plot. They were also subjected 
for peppas plot  in order to find out the mechanism of release from the prepared tablets . The 
kinetic analysis data of all the formulations were shown in Table no 28. 
The kinetic model that best fits with the release data of formulation was evaluated by the 
correlation coiefficient (R2) values. According to the values obtained it was found that F-1, F-2, 
F-6, F-7 and F-8 showed a higher linearity with zero order plots with R2 values ranging from 
0.953 to 0.969 indicating controlled release of drug from the prepared formulation . Formulation 
F-3, F-4, F-5 and F-9 gave a best fit for  first order equation describing drug release rate with 
concentration of drug. 
 
Mechanism of drug release:  
Mechanism of drug release data can be assist by plotting the drug release data with Koresmeyer-
peppas equation. The release exponent (n) value indicates the mechanism of drug transport from 
the matrix system. When the n value is equal to 0.5 indicates Fickian diffusion or anomalous, 
0.45-0.89 indicates non-fickian transport more than 0.89 indicates Super case II transport. 
The slope values obtained from the formulation ranged from 1.629 to 2.071 revealed the fact that 
drug release follows super case II transport diffussion posibly due to polymer chain errosion and 
swelling. 
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Table 28: Release kinetics parameter  
Formulation Zero order First order Higuchi Koresmeyer-
peppas 
Hixon 
crowell 
R2 R2 R2 R2 n R2 
F1        0.956 0.841 0.845 0.939 1.986 0.910 
F2 0.960 0.844 0.830 0.890 2.071 0.895 
F3 0.915 0.925 0.876 0.883 1.893 0.783 
F4 0.891 0.949 0.899 0.871 1.779 0.709 
F5 0.906 0.914 0.889 0.856 1.795 0.742 
F6 0.953 0.908 0.893 0.870 1.748 0.912 
F7 0.956 0.829 0.862 0.847 1.722 0.832 
F8 0.969 0.825 0.876 0.919 1.629 0.804 
F9 0.899 0.940 0.831 0.882 1.633 0.800 
 
6.10 Stability study 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of environmental 
factors such as temperature, humidity, and light, and to establish a re-test period for the drug 
substance or a shelf life for the drug product and recommended storage conditions. Formulation 
F8 which was chosen as the best one was loaded at accelerated condition at 400C±20C and 75% 
RH±5%RH in a stability chamber. Samples were withdrawn at 30, and 60, days and analyzed 
suitably for the drug content and drug release and the results are shown in Table 29.  
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Table 29:  Stability study of Tramadol hcl Tablets formulation 8: 
 
 
 
Duration 
 
 
 
 
Drug content 
(%) 
 
Percentage cumulative drug release 
 
 
pH1.2 
 
pH7.4 
 
pH6.8 
 
Initial 
 
99 
 
0 
 
7.13 
 
99.04 
 
30 Days 
 
98 
 
0 
 
6.8 
 
97.78 
 
60 Days 
 
99 
 
0 
 
8.1 
 
98.45 
 
 
The results of stability studies indicate no significant changes in the drug content and drug 
release characteristics which provide evidence for better stability of the prepared formulations in 
accelerated stability conditions. It also suggests that the ingredients used in the formulations 
were compatible with each other and no interactions were found between them. 
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9. SUMMARY 
 
The present study was aimed to prepare colon targeted tablets containing Tramadol HCl 
as active pharmaceutical agent and Eudragit E100 and Eudragit S100 as pH dependent polymers 
and to study the effect of these polymers on drug release rate. Since the oral bioavailability of 
Tramadol HCl is poor due to first pass metabolism, colon targeted tablets can be used as a 
promising formulation to by-pass the first past effect and thereby improve bioavailability.  
 
Formulation 
Colon targeted tablets of Tramadol HCl was formulated by using a different pH 
dependent polymers such as Eudragit E100 and Eudragit S100. Different layers of polymers has 
been coated on the core tablet by using HPMC as a barrier layer coat to avoid all possible 
interaction between Eudragit E100 and S100 since they are oppositely charged and different 
plasticizers were also used to give a proper coating and strength to the tablet. The coating of pH 
dependent polymers was done at three coating levels to give a net weight increase of about 3, 6 
and 9% respectively.  The barrier layer coat with HPMC was done to a constant weight increase 
of about 5%. Thus the core tablets have three layers coating comprising Eudragit S100 as the 
outer coat, HPMC as the middle layer barrier coat and Eudragit E100 as the innermost coat. 
 
Evaluation 
Evaluation studies were performed which includes all the preformulation and post 
formulation studies. The core and coated tablets evaluation studies includes hardness, friability, 
weight variation, drug content, thickness test and weight gain after each successive coating. 
In vitro drug release study was done in USP type II Paddle apparatus in different pH 
media such as pH1.2 for two hours, pH7.4 for three hours and pH6.8 for nineteen hours to mimic 
the intestinal pH and transit time. Sampling was done in prescribed time limit and analyzed for 
drug content using UV spectrophotometer for calculating the drug release. 
IR studies were done to confirm the compatibility of the pure drug and polymers. 
Stability studies were also performed for the best formulation for a period of 60days by storing 
the product in accelerated temperature and humidity conditions in a stability chamber and 
observed for any changes in appearance and drug release rate from the formulation. 
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Results and Discussion 
 
The preformulation studies performed on the powder blend showed satisfactory results with 
respect to the flow property and compressibility. The values obtained as angle of repose and 
compressibility index suggested that the prepared blend is well suitable to be compressed as 
tablets using direct compression method. The tablets were compressed by using 16 station rotary 
compression machine and the prepared tablets were found to be uniform in shape and size, with 
smooth surface and texture. There were no processing problems encountered during the 
compression process. Coating of the core tablets were done by using three polymers in the 
following order: Eudragit E100 – HPMC – Eudragit S100. The innermost layer was the acid 
soluble E100 polymer, the middle layer was HPMC which acts as the barrier coat and the 
outermost layer was S100 which is a gastro resistant polymer. Coating was done to three levels 
of weight gain i.e 3, 6 & 9% for E100 and S100, and weight gain was kept at a constant 5% for 
HPMC coating. 
 
The coated tablets were evaluated for weight gain after each coating levels to ensure the 
efficiency of the coating process. Further the tablets were also subjected to various evaluation 
parameters prescribed for coated tablets. The post compression evaluation of the coated tablets 
were found be within the prescribed limits of Indian Pharmacopeia with respect to weight 
variation, friability, content uniformity etc.  
 
The drug release studies were performed in three different media mimicking the various areas of 
the GIT viz. stomach, intestine and colon. Studies were done for a period of 24h which includes 
2h in gastric medium, followed by 3h in intestinal medium and remaining 19h in colonic 
medium. All the nine formulations did not produce any drug release in the first 2h in gastric 
medium except F-1 which gave a release of about 3% indicating that Eudragit S100 coating was 
done effectively, which protected the drug in the acidic environment.  
The drug release in the intestinal conditions was found to be in the range of 6.22% to 51.07% in 
the next three hours. The data suggest that as the polymer concentration was increased the drug 
release was found to be decreased. Formulation F-1 with 3% levels of E100 and S100 gave a 
release of about 51.07% whereas F-9 with 9% E100 and S100 gave only 6.22% which supports 
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the above statement. Similarly in the colonic pH conditions also, the release was found to be 
following the same pattern as that of in the intestinal conditions. Careful analysis of the drug 
release data revealed the fact that formulations F8 and F9 gave more than 90% release in the 
colonic pH conditions with less than 10% release in the gastric and intestinal conditions. Hence 
these two formulations were seems to be more appropriate for delivering maximum drug to the 
colon. Out of these two, formulation F8 with 9% S100 and 6% E100 coatings was selected as the 
best formulation based on the fact that it gave 93% release in the colonic condition and also gave 
100% release in 24h, whereas formulation F9 with 9% Eudragit E100 and Eudragit S100 coating 
although gave more than 90% release in colon, could only produce 83% release in 24h. 
 
Kinetic analysis of the release data obtained from the formulations suggested that most of the 
formulations (F1, F2, F6, F7 & F8) showed high linearity for zero order equation followed by 
first order kinetics (F3, F4, F5 &F9). The mechanism of release according to Peppas equation 
was found to be super case II transport, as the ‘n’ values were found to be more than 1, 
suggesting diffusion through polymer chain erosion and swelling. 
 
Stability studies indicated that the prepared formulations were stable at accelerated temperature 
and humidity conditions, showing no signs of physical or chemical degradation. 
 
Thus in this study, colon targeted delivery system for Tramadol HCl was formulated successfully 
and the results obtained from the work was encouraging. The optimized formula will be taken up 
for further studies for pilot scale up batch.  
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10. CONCLUSION 
Delivery of drugs to the systemic circulation without intermittent loss due to improper 
absorption, degradation in gastric conditions, first pass metabolism etc, is a challenging task for 
the formulation scientists. Although many approaches have been attempted for providing 
maximum bioavailability, colonic drug delivery has emerged as one of the promising method for 
improving bioavailability, targeting the drug for local effects in the colon, bypassing the first 
pass effect etc. 
In this study, we have made an attempt to develop an oral system for colon targeting using 
Tramadol HCl as the model drug. Nine formulations were developed by coating pH dependent 
polymers such as Eudragit E100 and S100 in different coating levels to delay the drug release in 
GIT. The observed results from the study have demonstrated the efficiency of these pH 
dependent polymers in delivering the drugs in the colonic region. It was also evident that when 
the coating levels of these polymers were increased, the drug release tends to slow down and 
thus enables the formulation to release the contents in colonic pH. Formulation F8 with 9% 
coating level of Eudragit S100 and 6% coating level of Eudragit E100 along with 5% HPMC 
barrier coating was found to be the optimized one as it showed more than 90% release in the 
colonic condition, with negligible release in the intestinal pH and it also gave a complete release 
in 24h. 
It can be concluded that, the combination of Eudragit E100 and S100 can be used effectively for 
colon targeting of drugs. Further animal studies for the in vivo results are necessary to claim 
complete success from the study.  
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